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Abstract 
The cellular prion protein (PrPC) is a glycoprotein with unknown function 
constitutively expressed in mammalian neurons. PrPC converts to a pathogenic 
misfolded isomer (PrPSc) through a poorly understood process, resulting in a 
group of fatal neurodegenerative diseases collectively known as transmissible 
spongiform encephalopathy or prion disease. Elucidating the molecular 
mechanisms behind prion conversion requires production of PrPC in recombinant 
systems. This study was designed to generate transgenic tobacco plants 
expressing recombinant mouse prion protein (mPrP). Using a synthetic gene 
encoding the mouse prion protein, plant expression vectors were constructed for 
constitutive mPrP expression in the apoplast (pGreen35SmPrP-Apo), cytosol 
(pGreen35SmPrP-Cyto) and endoplasmic reticulum (pGreen35SmPrP-ER). 
Putative transgenic plants transformed with either pGreen35SmPrP-Cyto or 
pGreen35SmPrP-ER were analysed by PCR, ELISA and immunoblot for 
transgene integration and expression. However, no viable plants were obtained 
from the pGreen35SmPrP-Apo transformants. ELISA analysis showed that 
recombinant mPrP accumulated up to 0.0024% of total soluble leaf protein in 
transgenic tobacco leaves transformed with the pGreen35SmPrP-Cyto construct 
and 0.0016% of total soluble leaf protein in plants designed to sequester 
recombinant mPrP to the ER. Furthermore, immunoblot analysis showed that ER-
targeted recombinant mPrP was mainly unglycosylated, although a glycosylated 
mPrP isoform was observed indicating that transgenic tobacco plants process 
ER-targeted recombinant mPrP in a manner analogous to mammalian systems. 
The nutrient composition of several transgenic plants were analysed to determine 
the phenotypic effect of expressing recombinant mPrP in tobacco plants. The 
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analysis revealed that transgenic lines expressing cytosolic-mPrP had elevated 
average levels of Mn2+ and Fe2+. In addition, kanamycin-treated transgenic plants 
expressing cytosolic-mPrP developed a non-rooting phenotype. Conversely, the 
average Cu2+ level was increased in analysed transgenic plants designed to 
sequester recombinant mPrP in the ER. Furthermore, the plants developed no 
visible phenotype upon kanamycin treatment. This result support studies that 
suggest that the PrPC has functional role in metal homeostasis and loss of its 
thermodynamic structure leads to metal dyshomeostasis which in turn has been 
linked to prion disease associated neurotoxicity. Finally, the recombinant mPrP 
was purified via affinity chromatography facilitated by the presence of a C-
terminal polyhistidine tag on the synthetic gene constructs.  
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Patience obtains all things 
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God alone suffices. 
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1.1 Prions 
The cellular prion protein (PrPC) is a glycoprotein that is highly conserved and 
constitutively expressed in mammalian neurons. The function of PrPC is unknown 
however the misfolded isoform of the protein causes prion disease (Prusiner, 
1998). Prion diseases are a group of progressive and fatal neurodegenerative 
disorders that affect both human and animals (Prusiner, 1998). The molecular 
basis for prion infectivity involves the post-translational conversion of cellular 
prion protein (PrPC) to an aberrant isoform, designated PrPSc, which causes prion 
disease (Prusiner, 1998; Piccardo et al., 2012). The PrPSc isoform is self-
replicating and propagates by converting newly synthesised PrPC into its aberrant 
isoform. This hypothesis is supported by the absence of infectivity in PrP 
knockout mice (Prusiner, 1998). In addition, synthetic PrPSc generated in vitro 
demonstrated low levels of infectivity in wild type animals (Weber et al., 2007). 
The entire open reading frame of the prion protein (PRNP) is located in a single 
exon of the prion protein gene (PRNP).  The PrPC and PrPSc isoforms have 
identical amino acid sequence but vary in their biochemical and biophysical 
properties due to post-translational modifications (McKintosh et al., 2003; Linden 
et al., 2008). 
1.1.1 Prion Protein Structure 
Full length human prion protein has 208 amino acid residues and consists of two 
domains (Figure 1.1). The N-terminal domain (23-120) is flexible and consists of 
4-5 octapeptide repeats with slight variation in consensus sequence 
(PHGGGWGQ) at amino acid residues 51-90. The C-terminal domain (121-231) 
folds into a stable conformation of three α-helixes (α-helix 1: 144–154, α-helix 2: 
173–194, and α-helix 3: 200–228) and an anti-parallel β-sheet (β1: 128-131 and 
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β2:161-164). The second and third α-helixes are stabilised by a disulphide bridge 
between Cys 179 and Cys 214. It also features sites for N-linked glycosylation at 
Asp 181 and Asp 197. A glycophosphatidylinositol (GPI) anchor linked at residue 
231 attaches the prion protein to the cell membrane (DeArmonda and 
Bouzamondo, 2002; Mastrianni, 2004).  
 
 
There are several structural differences between PrPC and PrPSc (Figure 1.2). The 
structure of PrPSc has not been elucidated due to methodological difficulties 
associated with the protein’s insolubility. Theoretically, PrPSc synthesis from 
recombinant PrPC involves disruption of the α-helixes and formation of an 
amyloidal β core, comprising of parallelly aligned β-strands at the C-terminal 
domain (Cobb and Surewicz, 2009). Fully glycosylated PrPC has a molecular 
weight of 33-35 kDa, is approximately 42% α-helical with 3% β-sheet, soluble in 
detergents and sensitive to proteinase K digestion while PrPSc is theoretically 
30% α-helical with 43% β-sheet, insoluble in detergents and proteinase K 
digestion of PrPSc results in an N-terminal truncated protease core (amino acid 
residues 90-231) of molecular weight of 27-30 kDa (DeArmonda and 
Bouzamondo, 2002;). 
Figure 1.1: Schematic representation of PrPC 
Reproduced with permission from Acevedo-Morantes and Wille (2014) 
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1.1.2 Function of PrPC 
Cellular prion protein is constitutively expressed by neurons and hematopoietic 
cells but the physiological function of cellular prion protein is yet to be elucidated. 
Several potential functions have been attributed to the cellular prion protein based 
on experimental observations including regulation of cell division and apoptosis, 
antioxidant activity, signal transduction, metal-ion transport and protection of 
neurons against Bax-mediated cell death (Hu et al., 2008; Jeffrey et al., 2012; 
Puoti et al., 2012). Researchers have observed that PRNP knockout mice are 
vulnerable to seizures and traumatic brain injury relative to wild-type mice. In 
addition, PRNP ablated mice exhibit normal early development but as they grow 
older the mice display severe ataxia and death of Purkinje neurons (Prusiner, 
1998). It is therefore, plausible that PrPC has a role in the development and 
protection of neurons (Hu et al., 2008). 
Figure 1.2: 3 Dimensional Structure of the PrP 
A, PrPC; B, Theoretical PrPSc  
Adapted from www.cmpharm.ucsf.edu/cohen 
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1.1.2.1 PrPC and Metal Interactions    
Prion protein binds several divalent transition metals including copper for which 
it has a high affinity. This affinity may signify a role for PrPC in copper metabolism 
and transport. Furthermore, PrPC affinity for metals indicates the protein may 
function as an antioxidant or influence metal-ion transport (Brown et al., 1999; 
Jeffrey et al., 2012). Brown et al. (1997) observed that compared to wild-type 
mice PRNP knockout mice have synaptosomal fractions that are deficient in 
copper strongly suggesting PrPC affects the delivery of copper to cells. Also, 
neurons from PRNP knockout mouse were more susceptible to oxidative stress 
and copper toxicity relative to wild-type neurons in a cell culture system. 
Consequently, this suggests that PrPC affinity for Cu2+ ion aids in protecting cells 
against copper toxicity and oxidative stress (Brown et al., 1999; Davies and 
Brown, 2008). The histidine residues within the octapeptide repeat region 
coordinate Cu2+ ions. The level of copper coordination is determined by the 
amount of copper that binds to PrPC. At full copper occupancy, the unstructured 
N-terminal region of the prion protein becomes more structured with altered 
biochemical properties. Also, Cu2+ ions bind to the hydrophobic region of the prion 
protein coordinated at histidine residues His 96 and His 111 (Davies and Brown, 
2008).   
The function of copper in the physiopathology of prion disease is subject to 
controversy. Evidence exists that copper binding prevents the conversion of PrPC 
to PrPSc and that copper bound PrPC has an increased α-helical content. Also, 
copper prevents the development of amyloid fibrils at physiological pH.  On the 
contrary, copper increases proteinase K resistance and induces aggregation in 
mature prion proteins. Furthermore, recombinant PrP bound to copper has higher 
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β-sheet content and compared to cellular PrPC are more prone to aggregation 
(Davies and Brown, 2008; Moore et al., 2009). 
These conflicting observations probably result from the different PrP purification 
methods that influence the prion protein affinity for copper and other divalent 
metals. In addition, the original conformation of the prion protein affects its affinity 
for metals and the metal-bound PrPC influence on protein aggregation (Moore et 
al., 2009). Finally, there is a possibility that alternate metal ion occupancy of PrPC 
is relevant in prion pathogenesis (Fontaine and Brown, 2009). For instance, brain 
tissues from sCJD patients showed increased levels of manganese and zinc-
bound PrPC whereas copper levels decreased relative to controls that had no 
detectable levels of manganese and zinc (Wong et al., 2001). 
1.1.3 Mechanism of PrPSc Aggregation 
Misfolded protein aggregation as shown in Figure 1.3, is a feature of common 
neurodegenerative disorders. The mechanism of prion protein aggregation has 
been modelled mainly on two kinetic theories (Figure 1.4). These models are 
template-assisted aggregation and nucleated polymerisation mechanism. In 
template-assisted aggregation, PrPSc acts as template to induce the 
conformational conversion of PrPC with the aid of a molecular chaperone termed 
protein X. Then, a heterodimer is formed between PrPC and PrPSc that assembles 
into fibrils. The nucleated polymerisation mechanism involves aggregation of 
PrPC monomers to form an oligomer PrPSc, which acts as a stable nucleus that 
integrates PrPC monomers, till amyloid fibrils are formed (Cobb and Surewicz, 
2009; Fontaine and Brown, 2009). PrPSc oligomers, consisting of 25 PrPC 
monomers, are the minimal infectious unit of prion disease (Cobb and Surewicz, 
2009). This implies that fragmentation of fibrils to oligomeric fractions by 
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molecular chaperones may contribute to disease pathology (Cobb and Surewicz, 
2009; Fontaine and Brown, 2009). Several factors including divalent transition 
metal ions, polyanions and glycosaminoglycans can influence prion protein 
aggregation (Fontaine and Brown, 2009).  
 
 
 
Figure 1.3: General mechanism of Protein aggregation 
Reprinted with permission from Dobson (2003). 
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The ability of misfolded protein monomers to form insoluble aggregates is 
described as seeding. In vitro, proteins associated with other neurodegenerative 
diseases such as Huntington’s, Alzheimer’s and Parkinson’s diseases display the 
seeding phenomenon but no evidence for infectivity. Therefore, studies of the 
prion phenomenon may have implications for other neurodegenerative diseases 
(Munch and Bertolott, 2012). In addition, the seeding phenomenon has been 
demonstrated in yeast.  Yeast “prion-like” protein [PSI+] regulated by molecular 
chaperone Hsp104 is cytoplasmically inherited where it modifies and induces 
aggregation of its newly synthesised monomeric form Sup35 (Cobb and 
Surewicz, 2009). 
 Recently, researchers observed that under ex vivo conditions human small heat 
shock protein sHspB5 regulates monomeric disaggregation of α-synuclein 
Figure 1.4: PrPSc aggregation models 
Reprinted with permission from Soto (2004). 
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amyloid fibres (pathogenic in Alzheimer’s and Parkinson’s diseases) by 
molecular chaperones Hsp40, Hsp70 and Hsp110. This indicates a potential 
strategy for treatment of neurodegenerative disorders (Duennwald et al., 2012). 
1.1.4 Prion Diseases 
Prion disease was first identified as scrapie in sheep and goats in the 18th century. 
Other examples of prion disease in animals include Bovine Spongiform 
Encephalopathy (BSE) of cattle, Transmissible Mink Encephalopathy (TME) of 
ranch-raised mink and Chronic Wasting Disease (CWD) of deer and elk 
(Prusiner, 1998).  Human prion diseases are classified according to etiology into 
sporadic, inherited or acquired. Sporadic prion diseases are generated through 
spontaneous conversion of PrPC to PrPSc or somatic mutation. Also, several 
researchers have associated the spontaneous occurrence of prion disease with 
oxidative stress (Jeffrey et al., 2012). Sporadic prion diseases include sporadic 
Creutzfeldt-Jakob disease (sCJD), which accounts for approximately 80% of 
human prion diseases and fatal sporadic insomnia (FSI) (Aguzzi and Calella, 
2009; Piccardo et al., 2012). The prevalence of sporadic CJD is estimated at 1 in 
1,000,000 annually (Hu et al., 2008).  
Inherited prion diseases may be due to point mutations in the C-terminal domain 
or octapeptide repeat insertions (OPRI) in the N-terminal domain of PRNP and 
are inherited in an autosomal dominant pattern (Prusiner, 1998; McKintosh et al., 
2003). The incidence of inherited prion disease is approximately 15% of human 
prion diseases. Conventionally, inherited prion diseases are classified based on 
neuropathological features and clinical symptoms into Gerstmann-Straussler-
Scheinker disease (GSS), Fatal Familial insomnia (FFI) and Familial CJD (fCJD) 
(Hill et al., 2006). Commonly investigated mutations include E200K of fCJD, 
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P102L of GSS and D178N of FFI and OPRI (Hill et al., 2006; Fontaine and Brown, 
2009). 
PrPSc cannot be degraded by proteases and conventional sterilisation methods, 
they are only destroyed by alkaline hydrolysis or incineration, hence its 
transmissible etiology (Prusiner, 1998). Peripheral pathogenesis of prion disease 
in humans occurs either orally or iatrogenically. Oral transmission is implicated in 
variant CJD by consumption of BSE contaminated beef and kuru in people who 
practiced ritualistic endocannibalism. Iatrogenic prion disease has been induced 
in patients through  transmission of prion infected blood and use of cadaveric 
human growth hormones and dura matter grafts that contained prion pathogen 
(Prusiner, 1998; Goni et al., 2005; Hu et al., 2008).  
1.1.4.1 PrPSc Strains 
Prion strains are a unique feature of prion diseases that are observed when a 
host species inoculated with a heterologous PrPSc agent displays a unique clinical 
phenotype different from the infectious species. In other words, prion strains are 
conformational variations of PrPSc (Caughey et al., 1998; Hu et al., 2008). The 
ease at which prion strains are generated poses a public health risk in the event 
that perilous new prion strains similar to vCJD emerge (Morales et al., 2007; 
Barria et al., 2009). The diversity of prion strains have been attributed to the 
conformational flexibility of PrPC, interspecies transmission and PrP 
polymorphisms (Prusiner, 1998; Morales et al., 2007; Cobb and Surewicz, 2009). 
For instance, varying clinical phenotypes for sCJD have been observed in 
patients characterised by homozygosity for methionine or valine and 
heterozygosity at codon 129 (Prusiner, 1998; McKintosh et al., 2003; Hu et al., 
2008; Puoti et al., 2012). 
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The term interspecies barrier refers to the ability of prion strain to infect only 
selected species (Castilla et al., 2008). On the other hand, interspecies barrier 
may be defined as the long incubation period and low transmission rate observed 
when PrPSc strains are transmitted to a heterologous species. This suggests that 
the PrPC sequence and cellular environment of the host determines prion disease 
pathology (Cobb and Surewicz, 2009; Fontaine and Brown, 2009). The donor 
prion strain and differences in the amino acid sequence between the prion host 
and donor species determines interspecies barriers (Prusiner, 1998; Piccardo et 
al., 2012). Crossing the interspecies barrier generates a new PrPSc strain and 
subsequent passages of the new strain in homologous host species stabilises the 
new prion strain conformation (Castilla et al., 2008). The mouse-hamster species 
barrier was crossed in vitro (Castilla et al., 2008), using a process known as 
protein misfolding cyclic amplification (PMCA) (Saborio et al., 2001), this process 
was previously thought unattainable given lack of symmetry between mouse and 
hamster generated PrPSc fragments. The generated synthetic prion strain 
demonstrated infectivity in wild type animals (Castilla et al., 2008).  
1.1.4.2 Prion Disease Diagnosis and Treatment 
Prion diseases are associated with relatively long incubation periods usually 
exceeding three decades and diagnosis is usually by onset of clinical symptoms 
(Prusiner, 1998). Prion disease strains are confirmed at autopsy by 
histopathological examination of brain and central nervous system (CNS) tissues. 
The disease strains are characterised by western blot analysis, neuropathology 
and immunohistochemistry (McKintosh et al., 2003; Jeffrey et al., 2012). Strains 
can be classified in vivo by variation in vacuolation profile, clinical symptoms and 
incubation period (Prusiner, 1998; Morales et al., 2007; Hu et al., 2008; Piccardo 
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et al., 2012). Biochemically, differences in prion strains are diagnosed by their 
glycosylation profile, exposure to denaturing solvent guanidine hydrochloride and 
varying electrophoretic mobilites after protease digestion (Morales et al., 2007; 
Piccardo et al., 2012; Puoti et al., 2012). However, several PrPSc strains in cattle, 
humans and sheep are susceptible to protease digestion. Fortunately, the 
specificity of immunohistochemistry identifies the differences between protease 
resistant PrPSc plaques and protease sensitive PrPSc plaques (McKintosh et al., 
2003, Jeffrey et al., 2012). The presence of prion proteins in the lymphoid tissues 
is also detected by immunohistochemistry (McKintosh et al., 2003). 
In brain tissues, immunohistochemical staining depends on the accumulation of 
PrPSc plaques in the brain (Jeffrey et al., 2012). However, prion diseases are not 
always associated with accumulation of PrPSc plaques indicating that 
immunolabelling may be insufficient for diagnosis (Jeffrey et al., 2012). Currently, 
prion disease strain can be identified efficiently in patients who have undergone 
cerebrospinal fluid (CSF) analysis, electroencephalography (EEG), brain biopsy 
and magnetic resonance imaging (MRI).  Also, gene sequencing can identify 
inherited forms of prion disease and eliminate several strains (Puoti et al., 2012). 
There is a need for diagnostic techniques for easy detection of PrPSc in bodily 
fluids as this will allow pharmacological intervention before onset of clinical 
symptoms (Hu et al., 2008). The diverse prion strains hinder the development of 
a simplified diagnostic procedure because it is almost impossible to exploit PrPSc 
biophysical characteristics as an in vitro marker of infectivity (Baskakov and 
Breydo, 2007). 
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No successful therapies for human prion disease exist. However, immune 
modulation may prevent prion infectivity and delay clinical onset of disease (Goni 
et al., 2005; Hu et al., 2008; Puoti et al., 2012).  
1.1.5 Glycosylation profile of PrP 
Post-translational modifications may alter PrPC conformation making it amenable 
for conversion to PrPSc (Prusiner, 1998). PrPSc strains have varied affinities for 
different PrPC glycoforms (Rudd et al., 2002). Therefore, glycosylation modulates 
PrPSc stability and its incubation period prior to disease onset (Prusiner, 1998). 
The distribution of the diverse glycoforms in a prion strain can be characterised 
using SDS-PAGE analysis (Cobb and Surewicz, 2009). However, the diagnostic 
value of this is limited as prion strains may have similar glycoform ratios (Rudd et 
al., 2002). For instance, in inherited prion disease, point mutations P102L, D178N 
and E200K have similar glycosylation patterns (Hill et al., 2006). The 
glycosylation pattern of infectious PrPSc strain is maintained by the host cells 
(Rudd et al., 2002). Consequently, the glycosylation pattern of a PrPSc strain may 
help explain its neurological phenotype (McKintosh et al., 2003). For instance, 
similarities between diglycosylation patterns of vCJD and BSE contributed to the 
theory that vCJD is the human variant of BSE (Yin et al., 2003). Glycosylation 
patterns may also affect the stability of amino acid residues involved in prion 
homodimer formation. This implies that understanding glycosylation patterns may 
aid in elucidating PrPSc-PrPC heterodimer structure (Rudd et al., 2002). Hence, 
analysis of the biochemical and biophysical properties of PrPSc glycoforms would 
require substantial quantities of PrPC glycoforms (Rudd et al., 2002). This 
indicates that recombinant expression systems capable of glycosylation are 
essential for the production of PrPC.  
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In mammals, transgenic mice and hamsters expressing recombinant PrPC are 
the main models for investigating prion phenomenon. However, difficulties 
associated with purification of recombinant PrPC from brain tissues resulted in 
low yields (Yin et al., 2003; Vrentas et al., 2012). Alternatively, sufficient amounts 
of recombinant PrPC can be produced in an Escherichia coli bacterial expression 
system (Yin et al., 2003; Pavlicek et al., 2007). But, prion proteins produced in 
bacteria tend to form inclusion bodies and subsequent purification of inclusion 
bodies may modify the protein, altering its native conformation (Corsaro et al., 
2002; Abskharon et al., 2012). Also, bacterially expressed recombinant PrPC are 
unglycosylated. Glycosylation has no effect on PrPSc infectivity, although it 
modifies the infection process, hence there is a possibility glycosylation affects 
PrPSc conformation (Pavlicek et al., 2007; Tuzi et al., 2008). Therefore, 
biochemical and structural studies using recombinant PrP from bacteria, may not 
fully resolve the molecular mechanisms of prion diseases.  This dilemma could 
be possibly circumvented by using transgenic plants as a novel source of 
recombinant PrP since plant expression systems offers the advantage of 
producing the different PrP glycoforms. 
1.2 Transgenic Plants  
Plants are established production system for recombinant protein. Molecular 
farming is the use of transgenic plants to produce commercially significant 
biopharmaceuticals such as vaccines, enzymes, therapeutic antibodies and 
growth hormones (Daniell et al., 2001; Goldstein and Thomas, 2004; Twyman et 
al., 2005). Examples of important biopharmaceuticals produced in transgenic 
plants is shown in table 1.1. The use of transgenic plants as an expression 
system offers advantages in terms of inexpensive production costs, low risk of 
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contamination with microbial toxins and mammalian pathogens, specialised 
organs for storing the recombinant protein, scalability, and potential for post-
translational modification (Ma et al., 2003; Twyman et al., 2005). Recombinant 
protein yield in plants is determined by several factors including choice of host 
plant, design of transgene construct and transformation method. 
 
Recombinant 
protein 
Host 
plant 
Vector/ 
Transformation 
technique 
Expression 
level 
Notes 
 
 
Alkaline 
phosphatase 
 
 
Tobacco  
 
 
pBinAR/AMT 
 
 
3% tsp  
 
 
Used to treat ovarian 
and testicular cancer 
Aprotinin Maize PB 6% tsp Used as trypsin 
inhibitor during 
transplant surgery and 
for treatment of 
pancreatitis 
  
Avidin Maize PB 3% tsp Used in biochemical 
assays. 
First commercially 
produced plant 
biopharmaceutical 
Commercially 
produced by 
ProdiGene 
Cholera toxin B 
subunit 
Potato 
Tomato 
Tobacco 
pPCV701/AMT 
pCAMBIA2301/
AMT 
pLDCtV2/PB 
0.3% tsp 
0.04% tsp 
4.1% tsp 
First chloroplast 
expressed vaccine 
The recombinant 
vaccine was 
immunogenic and 
protective in mice 
when delivered orally 
Collagen Tobacco pBINPLUS/AMT 2% tsp Used to repair 
damaged tissue 
First successful 
expression of a 
correctly modified 
human structural 
protein polymer 
Commercially 
produced as Vergenix 
by Collplant 
Erythropoietin Tobacco 
cells 
pCAM35/ 
protoplast 
electroporation 
1 pg/g wet 
cell 
Used to treat anaemia 
Initial human protein 
expressed in tobacco  
suspension cells 
Table 1.1 Important biopharmaceuticals produced in transgenic plant systems 
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Glucocerebrosidase Carrot 
cells 
Tobacco 
pGREENII/AMT 
 
pBI101/AMT 
 
 
 
Used to treat 
Gaucher’s disease 
Commercially 
produced by Protalix 
Bio-Therapeutics 
Herpes simplex 
virus antibody 
Soybean   First expression of a 
biopharmaceutical in 
soybean  
Hepatitis B surface 
antigen 
Banana 
Potato 
Tobacco 
pBI121/AMT 
pBI121/AMT 
pBI121/AMT 
0.7µg/g FW 
97.1 ng/g 
FW  
66 ng/mg tsp 
Immunogenic in 
human and mice when 
orally administered 
Commercially 
produced by Arizona 
University 
α-Interferon Rice 
Carrot 
cells 
Tobacco 
pG121Hm/AMT 
pCBV16/ 
Vacuum 
infiltration 
PB 
 
 
 
3 mg/g FW 
First 
biopharmaceutical 
produced in rice 
Used to treat Hepatitis  
Commercially 
produced by Biolex 
Lactoferrin Rice 
Tobacco 
Sweet 
Potato 
pAPI141/PB 
pCGN1578/AMT 
pGA748/PB 
20% tsp 
4.3% tsp 
3.2 µg/mg 
tsp 
Antimicrobial 
Commercially 
produced by Ventria 
Bioscience 
Rabies Virus 
Glycoprotein 
Tomato 
Tobacco 
 
RG-2/AMT 
Pbi101/AMT 
 
10ng/mg tsp 
0.38% tsp 
Rabies vaccine, 
immunogenic in mice 
when orally 
administered. First 
edible vaccine 
biopharmaceutical 
Zmapp (C13C6, 
C2G4 & C4G7 Ebola 
antibodies) 
Tobacco BeYDV/ 
Agroinfiltration 
50 µg/g FW Used to treat  Ebola 
Commercially 
produced by Mapp Bio 
Serum Ablumin Tobacco 
Potato 
pLD/PB 
pTUB3/AMT 
11% tsp  
0.2% tsp 
Used to treat burns 
and liver cirrhosis 
First full size 
biopharmaceutical 
expressed in plants. 
Somatotropin Tobacco pPRV112B, 
pPRV111B/PB  
7% tsp - 
chloroplast 
Used to treat pituitary 
dwarfism 
First human 
biopharmaceutical 
expressed in plants 
and chloroplast  
AMT – Agrobacterium mediated transformation; PB – Particle Bombardment                                              
(Adapted from Daniell et al., 2001; Ma et al., 2003; Twyman et al., 2005; Moustafa et al., 2016) 
 
1.2.1 Choice of Plant 
Recombinant proteins have been produced in a variety of plant species. 
Transgenic plants are generally classified as leafy crops, fruits & vegetables, oil 
& fibre crops and cereal & legume seed. Leafy crops such as Arabidopsis thaliana 
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and Medicago sativa, offers high biomass yield but must be processed or frozen 
at maturity to prevent protein degradation (Twyman et al., 2003; Fischer et al., 
2004). Accumulation of recombinant protein in seeds, for instance, soybean and 
maize, supports long-term storage of recombinant protein, however, potential 
problems of gene transfer through pollen needs to be addressed (Schillberg et 
al., 2005; Obembe et al., 2011). Fruits & vegetables, for example tomatoes and 
potatoes, are desirable for the production of edible vaccines and topically applied 
antibodies due to minimal downstream processing requirements (Twyman et al., 
2005). Recombinant proteins have been targeted to the oil bodies of safflower 
and rapeseed plants, using the oleosin-fusion technology, to simplify the 
purification process (Giddings et al., 2000; Ma et al., 2003). Fibre crops such as 
cotton, offer alternative by-products, which may help offset recombinant protein 
production costs (Twyman et al., 2003).  
In this study designed to produce recombinant mouse prion protein (mPrP) in a 
plant expression system, tobacco was chosen as the host plant. Tobacco is a 
model laboratory plant with abundant literature on transgene expression. 
Extensive research on transgenic tobacco has resulted in established protocols 
for gene transfer and gene expression. Also, tobacco is environmentally safe 
because it is a non-food/feed crop and can be produced under greenhouse 
conditions. Finally, tobacco plants are easily regenerated using 
micropropagation, have a biomass yield of 100,000kg per hectare and have 
established prime, large-scale downstream processing facilities. However, 
tobacco leaves must be processed immediately after harvest to avoid loss of the 
recombinant protein and also the presence alkaloids in tobacco may interfere with 
downstream processing (Twyman, 2006). 
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1.2.2 Transgene Design 
Efficient transgene design affects the yield of recombinant proteins. The use of 
regulatory elements, codon optimisation, and signal sequence for subcellular 
localisation in the transgene construct mostly improves recombinant protein yield. 
Transcriptionally gene expression can be controlled by use of suitable promoters. 
Promoters are important cis-regulatory elements that modulate the rate of 
transgene expression. They are classified according to their mode of operation 
into constitutive, tissue-specific, inducible and synthetic promoters (Sharma and 
Sharma, 2009; Hernandez-Garcia and Finer, 2014).  Constitutive promoters drive 
transgene expression in all plant tissues and at all developmental stages of the 
plant. Conventional constitutive promoters include CaMV 35S promoter isolated 
from cauliflower mosaic virus for dicotyledonous plants (Odell et al., 1985) and 
maize ubiquitin promoter for monocotyledonous plants (Christensen and Quail, 
1996). However, the overexpression of certain transgenes may be toxic to the 
plant, thus the need for regulated promoters. 
Tissue-specific promoters restrict transgene expression to certain tissues, organs 
or developmental stages of the plant (Sharma and Sharma, 2009).  Seed-specific 
promoters are the most common tissue specific promoters and limit transgene 
expression to seeds. For example, rice globulin 1 promoter was used to express 
human lysozyme in maize endosperm (Yang et al., 2003).  Inducible promoters 
regulate transgene expression by responding to external stimuli. This stimulus 
may be chemical, physical or endogenous. Notable inducible promoters include 
the tetracycline inducible promoter, the most studied chemically inducible plant 
promoter system, and the wheat wcs120 promoter, a cold inducible promoter that 
has been tested in wheat, barley and alfalfa (Corrado and Karali, 2009).  
19 
 
The limitations of natural promoters in transcription efficiency, induction 
conditions and size has led to a demand for synthetic promoters in plant 
transgenic technology. Synthetic promoters are enhanced natural promoters with 
tetrameric repeats of regulatory elements to improve strength and/or specificity 
of the promoter (Hernandez-Garcia and Finer, 2014). Synthetic promoters, such 
as the MAC promoter derived by combining the MAS element of Agrobacterium 
and the CaMV35S promoter, by comparative analysis are more effective than 
natural promoters at improving transgene expression (Hernandez-Garcia and 
Finer, 2014).  
Translational efficiency of the transgene can be improved by modifying codon 
usage and addition of intronic elements. Codon optimisation involves using codon 
usage tables to alter the coding sequence of the transgene to closely match 
preferred genes of the host species (Koziel et al., 1996; Kusnadi, 1997). The 
entire sequence of the transgene may be altered or only codons below a certain 
threshold in the host species are changed. The results are usually unpredictable, 
ranging from enhanced expression to no effect. Researchers usually test multiple 
optimised gene designs to determine the best construct for stable and enhanced 
expression. Also, codons may be optimised to increase GC content, remove RNA 
motifs associated with poor expression and alter sequences targeted by 
endogenous small RNAs involved in silencing (Rouwendal et al., 1997; Lessard 
et al., 2002). Plant viral mRNAs are effective enhancers of translation.  5’ and 3’ 
untranslated regions (UTR) are highly structured intronic regions in viruses that 
are essential for replication and translation (Gallie and Walbot, 1990; Gallie, 
2002). The 5’ viral UTR contains signal for effective initiation of translation and 
contends efficiently with plant cellular mRNA for free ribosomes. In transgenic 
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tobacco plants, fusing the tobacco mosaic virus (TMV) 5’ UTR to the start codon 
increased transgene expression levels (Gallie, 2002) while the 3’UTR contributes 
to the stability and translational efficiency of the mRNA (Gallie and Walbot, 1990). 
The subcellular compartment, in which a heterologous protein accumulates, 
affects the associated processes of folding, assembly and post-translational 
modification, therefore, its yield (Schillberg et al., 2003; Twyman et al., 2003). 
Recombinant proteins without a signal sequence accumulate in the cytosol where 
they are usually quickly degraded by proteases. Also, proteins retained in the 
cytosol lack post-translational modification. Therefore, recombinant proteins can 
be targeted to the secretory pathway by adding an N-terminal signal sequence to 
the transgene construct. The protein is then secreted to the apoplast where they 
are retained (Conrad and Fiedler, 1998).  Accumulation levels of recombinant 
protein can also be increased 2 to 10-fold by retaining them in the lumen of the 
endoplasmic reticulum (ER) using the H/KDEL C-terminal tetrapeptide tag 
(Conrad and Fiedler, 1998). The ER is an oxidising environment, lacks proteases 
and contains molecular chaperones, essential factors for correct protein folding 
and assembly. Also, recombinant proteins retained in the ER are not altered by 
the Golgi apparatus, hence they have high mannose glycans but no plant-
associated xylose and fucose residues (Conrad and Fiedler, 1998). 
1.2.3 DNA delivery systems  
Heterologous genes are introduced into plant systems by established methods of 
co-cultivation with Agrobacterium tumefaciens (Holsters et al., 1978) and/or 
biolistics. Agrobacterium-mediated transformation is based on the ability of the 
bacteria to stably integrate a section of DNA within its tumour inducing (Ti) 
Plasmid into the nuclear genome of plants (Darbani et al., 2008). It is the most 
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efficient transformation method because it is associated with transfer of large 
DNA fragments, stable transgene integration into host genome, low transgene 
copy number, reduced transgene silencing and stable transgene expression in 
subsequent generations of transgenic plants (Hansen and Wright, 1999; Desai et 
al., 2010). However, Agrobacterium transformation is suited mainly to 
dicotyledonous plants although use of super virulent vectors enhances 
expression in monocotyledonous crops (Birch, 1997; Hansen and Wright, 1999). 
The transformation efficiency of   Agrobacterium can be improved by sonication 
of explants as this allows the Agrobacterium to access more plant cells (Trick and 
Finer, 1997). 
Biolistics involves microprojectile bombardment of target plant tissues with 
transgene-coated gold or tungsten particles. Methodological advantages include 
introduction of several transgenes at once into plant tissues and elimination of 
explant necrosis sometimes associated with Agrobacterium-mediated 
transformation (Birch, 1997; Darbani et al., 2008). However, integration of long 
DNA fragments can be problematic as the DNA is not protected from damage in 
cells and multiple copies of transgene integrate at the same site leading to gene 
silencing (Birch, 1997; Hansen and Wright, 1999; Darbani et al., 2008). A later 
development agrolistics, which involves co-bombardment of the transgene along 
with the virulence genes of Agrobacterium, has improved the efficiency of 
transgene integration using biolistics (Darbani et al., 2008). 
1.2.4 Glycosylation 
Protein glycosylation is an important post-translational modification for the correct 
function of many proteins in eukaryotes. Glycosylation significantly influences the 
physicochemical properties of proteins such as solubility and protection from 
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thermal and proteolytic degradation. It also modulates the biological properties of 
a protein including specific activity, ligand receptor interactions and 
immunogenicity (Gomord and Faye, 2004). Recombinant glycoproteins are 
usually associated with N-glycans or O-glycans. Both glycans differ in their sugar 
composition, biosynthesis and association with amino acid residues (Gomord et 
al., 2005; Faye et al., 2005). Although, the glycosylation capacity of plants makes 
them an attractive expression system their glycosylation patterns are structurally 
different from mammals (Gomord et al., 2005; Sethuraman and Stadheim, 2006). 
The possible immunogenicity of plant specific glycans may limit the use of plant-
made biopharmaceuticals for therapeutic purposes (Ma et al., 2003; Gomord et 
al., 2005; Faye et al., 2005).  
N-glycans are linked to the amide group of asparagine residues. Plants and 
mammals have similar N- type glycans in the endoplasmic reticulum (Lerouge et 
al., 2000).  However, further processing in the Golgi apparatus leads to dissimilar 
complex type N-glycans in plants and mammals. Plants have (1, 3)-fucose and 
(1, 2) – xylose residues while mammals have (1, 6)-fucose residues and (1, 
4)-galactose residues (Gomord and Faye, 2004). Several strategies to humanise 
plant N-glycans for the production of non-immunogenic recombinant proteins are 
being examined.  This includes processes to inactivate plant glycostransfearses, 
de novo expression of heterologous glycosyltransferases similar to those in 
mammals, RNA interference to reduce focosly and xylosyl glycans levels and 
retention of the recombinant protein in the endoplasmic reticulum (Ma et al., 2003; 
Lerouge et al., 2000; Sethuraman and Stadheim, 2006). For example, Zmapp an 
antibody cocktail for treatment of Ebola, is produced in Nicotiana benthamiana 
plants engineered to produce humanised glcans (Olinger et al., 2012) 
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O-glycosylation occurs in both intracellular and extracellular proteins. O-glycans 
are linked to the hydroxyl groups of serine or threonine residues in mammals and 
hydroxylproline residues in plants. Mammals have a preference for mucin type 
O-glycans while plants have a preference for hydroxylproline rich O-glycans of 
extensins and arabinogalactan proteins (AGP) (Gomord et al., 2010). Despite the 
problem of immunogenicity, the presence of plant-specific O-glycans can improve 
protein stability and resistance to proteolysis. For example, AGP O-linked 
glycomodule in chimeric human interferon 2b (IFN2) improved protein stability 
and increased recombinant protein yield up to 1400-fold (Xu et al., 2007).  
1.2.5 Downstream Processing 
The downstream processing requirements for any heterologous protein depends 
on the proposed use of the recombinant protein. For instance, edible vaccines 
require no downstream processing while a recombinant protein required for 
pharmaceutical or diagnostic purposes requires a high purification threshold 
(Menkhaus et al., 2004). Downstream processing is the most expensive aspect 
of recombinant protein production in transgenic plants (Nikolov and Woodard, 
2004). Insufficient data on recombinant protein purification is probably because 
of suboptimal expression levels and substandard purification processes (Nikolov 
and Woodard, 2004).  Therefore research to identify easily scalable, efficient and 
economical purification is important to reduce the significant downstream 
processing costs associated with plant based systems (Nikolov and Woodard, 
2004; Menkhaus et al., 2004). There are several ways to design transgenic plants 
to reduce processing costs. For example, targeting the recombinant protein to 
tissues such as maize seed, which are easily separated from other plant tissues, 
reduces purification burden (Kusnadi et al., 1997).  
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The efficiency of recombinant protein purification from plants is influenced by the 
host system, purification requirements and the concentration of the recombinant 
protein (Wilken et al., 2012). The recombinant protein is released from seed-
based and leaf-based production systems by homogenisation of the biomass 
followed by buffer extraction and centrifugation to clarify the extracts. Detergents 
are a necessary buffer additive for extraction of membrane-associated proteins 
(Kusnadi et al., 1997; Wilken et al., 2012). Protease inhibitors and antioxidants 
are usually added to extraction buffers to prevent structural modification of the 
recombinant protein due to proteolytic activity and interaction with phenolic 
compounds (Kusnadi et al., 1997). Prior to purification, plant extracts are pre-
treated to remove most of the host plant proteins and contaminants. Pre-
treatment strategies include pH adjustment, aqueous two-phase extraction and 
precipitation followed by another clarification step (Wilken et al., 2012). Most 
purification strategies usually involves chromatography. Affinity chromatography 
based on a Protein A or G ligand is used for purifying antibodies while histidine-
tagged proteins are purified using immobilised-metal affinity chromatography 
(IMAC) (Wilken et al., 2012). For example, fusing a 6X His-tag to lactate 
dehydrogenase improved protein purification and increased the yield and purity 
of the recombinant protein (Mejare et al., 1998). However chromatographic 
purification is not commercially scalable because of resin fouling (Menkhaus et 
al., 2004).  
1.3 Research Aims 
This research aims to investigate the possibility that recombinant mPrP produced 
in transgenic tobacco plants, may better reflect the properties of the prion protein 
in experimental studies. By directing heterologously expressed mPrP to the ER, 
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post-translational glycosylation will produce a recombinant protein more 
representative of mammalian protein than that expressed in E.Coli. 
 The research objectives include  
 Design of transgene constructs  
 Characterisation of transgenic tobacco plants expressing recombinant 
mPrP 
 Phenotypic analysis of transgenic tobacco leaves expressing recombinant 
mPrP 
 Purification of recombinant mPrP from transgenic tobacco leaves  
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2 Materials and Method 
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2.1 Introduction 
This chapter details the experimental procedures used in this study. Except 
where stated, all protocols were carried out according to manufacturer’s 
guidelines. Antibiotics were obtained from Melford Laboratories Ltd and the 
various growth media reagents from Sigma-Aldrich. GraphPad prism 7 software 
was used for data analysis. 
2.2 Design of transgene construct 
2.2.1 Bacterial strains 
Escherichia coli strain DH5α [fhuA2Δ (argF-lacZ) U169 phoA glnV44 Φ80Δ (lacZ) 
M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17] (Hanahan, 1985) was procured 
from New England Biolabs and used for all molecular cloning procedures. 
Agrobacterium tumefaciens strain AGL1 [AGL0recA::blapTiBo542deltaT 
Mop+ CbR] (Lazo et al., 1991) used for all plant transformation procedures was 
provided by David Bringloe’s Laboratory at University of East London. 
2.2.2 Plant growth conditions 
Nicotiana tabacum L. cultivar Samsun was provided by David Bringloe’s 
Laboratory at the University of East London. The plants were grown under aseptic 
conditions in Phytatray(s) II (Sigma-Aldrich) placed in an incubator (LMS 600 
Series 4 Cooled Incubator) at 25°C under a 16:8 light: dark photoperiod.  
2.2.3 Transgene design 
The mouse PRNP gene was codon-optimised for expression in the nuclear 
genome of tobacco plants using GENEius software (Eurofin Genomics).  Three 
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synthetic constructs were designed to direct gene expression to various 
subcellular locations.  Subsequently, the synthetic constructs were synthesised 
by Eurofins MWG Operon and delivered inserted into the NotI site of the pEX-A 
vector.  
2.2.4 Plasmids 
2.2.4.1 35S-CaMV 
The 35S CaMV cassette (Figure 2.1) contains a promoter and terminator region, 
cis-acting factors, essential for constitutive expression of a foreign gene in 
transgenic plants (Hellens et al., 2000). It also features a multiple cloning site 
(MCS) for insertion of the transgene between the promoter and terminator region. 
The vector backbone pJIT60 has an ampicillin resistance gene for selection of 
transformants in E. coli.  
 
 
 
Figure 2.1: 35S-CaMV cassette  
Reproduced from www.pgreen.ac.uk 
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2.2.4.2 pGreen 
A   
B   
 
 
 
Figure 2.2: pGreen Binary Vectors 
A: pGreen plasmid map. B: pSoup plasmid map. 
Reproduced from www.pgreen.ac.uk 
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The plasmids pGreen0029 and pSoup (Figure 2.2) are binary vectors created for 
Agrobacterium-mediated plant transformation. The pGreen vector features a 
pSa-ori (origin of replication) gene, kanamycin resistance NptI gene and a 
pBluscript based MCS. The pSoup construct contains a pSa-RepA gene for in 
trans replication of pGreen0029 in Agrobacterium (Hellens et al., 2000).  
2.2.5 Expression cassette construction 
2.2.5.1 Restriction digestion 
Recombinant plasmids were digested with the appropriate FastDigest restriction 
enzymes (Thermo Fisher Scientific) in 20 µl reaction volume. For subcloning 
reactions, restriction digests were carried out 100 µl reaction volume for 1 hour. 
Afterwards, digested samples were analysed using agarose gel electrophoresis.  
2.2.5.2  Agarose gel electrophoresis  
Agarose gels (1-2%) were prepared for analysis of DNA samples in 1X TAE buffer 
(1 Litre: 40 mM Tris (pH 7.6), 20 mM Acetic acid and 1 mM EDTA). To visualise 
DNA fragments, SYBR Safe stain (Invitrogen) was added to molten agarose while 
DNA gel loading dye (Thermo Fisher Scientific) was added to DNA samples in a 
1:5 ratio before electrophoretic analysis. The gels were submerged in HU6 mini 
electrophoresis tanks containing 1X TAE buffer and 20 µl or 50 µl samples were 
electrophoresed at 75 volts for ~ 45 minutes. Results were then visualised on an 
ultraviolet transilluminator (ChemiDoc MP Imager, Bio-Rad). 
2.2.5.3 DNA recovery  
DNA fragments required for subcloning reactions were excised from 
electrophoresed gels. The DNA fragments were visualised with UV light on a 
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ChemiDoc MP imager (Bio-Rad) and excised with a scalpel. Subsequently, the 
DNA fragments were extracted from the gel slices using QIAquick Gel Extraction 
Kit (Qiagen).  
2.2.5.4  Subcloning procedure 
Subcloning procedure was as described by Sambrook et al. (1989). Purified DNA 
fragments excised from the recombinant vectors pEX-A-mPrP or pJIT-mPrP were 
ligated into restriction enzyme sites of linearised pJIT or pGreen plasmid 
respectively using Lyo-Ligase (Bioline). Linearised plasmids were 
dephosphorylated with Antarctic Phosphatase (New England Biolabs) to prevent 
religation of the plasmid since a single restriction enzyme was used for all pGreen 
subcloning procedures. The dephosphorylated pGreen vector was purified with 
the MinElute Reaction Cleanup Kit (Qiagen) before the ligation process.  Ligation 
reactions were incubated overnight at 16°C, then purified with the MinElute 
Reaction Cleanup Kit (Qiagen) before E. coli transformation.  
2.2.5.5 E. coli transformation  
Purified recombinant plasmids (5ng) were added to 50 µl ice-cold 
electrocompetent DH5α cells (New England Biolabs) and mixed. The mixture was 
transferred to a 1 mm electroporation cuvette (Bio-Rad) and electroporated using 
the MicroPulser Electroporator (Bio-Rad). Luria-Bertani (LB) broth (1 Litre: 10 g 
tryptone, 10 g NaCl and 5 g yeast extract) was added in 0.95 ml aliquots to the 
electroporated cells and gently mixed. The mixture was incubated at 37°C for 1 
hour in an Eppendorf thermomixer at 100 rpm to induce expression of the 
plasmid’s antibiotic-resistance gene.  Subsequently, the transformed cells were 
pelleted by centrifugation at 13,000 rpm for 1 minute and resuspended in 200 µl 
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LB broth. 50 µl of the suspension was spread on LB plates (1 Litre: LB broth and 
15 g agar) supplemented with either kanamycin (100 µg/ml) or ampicillin (100 
µg/ml) depending on the selective marker expressed by the plasmid. The LB 
plates were then incubated at 37°C overnight.   
2.2.5.6 Plasmid DNA isolation  
Recombinant pJIT-mPrP and pGreen-35S-mPrP plasmids were isolated from 
transformed E. coli. DH5α colonies using a QIAprep Spin Miniprep Kit (Qiagen). 
Afterwards, the integrity of the recombinant plasmids was confirmed by restriction 
enzyme analysis as described (Sections 2.2.5.1 and 2.2.5.2) 
2.2.6 Transformation of tobacco leaves 
2.2.6.1 Preparation of electrocompetent cells  
Electrocompetent Agrobacterium AGL1 cells were prepared as described by Lin 
(1995) and Den Dulk-Ras & Hooykaas (1995). A 200 µl aliquot of log phase AGL1 
stock was added to 100 ml of YEP broth (1 Litre: 10 g peptone, 10 g yeast extract 
and 5 g NaCl) containing rifampicin (100 µg/ml) and incubated at 28°C overnight 
in an orbital shaker at 300 rpm. Subsequently, cells were pelleted by 
centrifugation at 5,000 rpm for 10 minutes and washed 3 times in 20 ml of sterile 
ice cold glycerol and finally resuspended in 2 ml of sterile, ice-cold 1 M sorbitol. 
Electrocompetent AGL1 cells were stored in 100 µl aliquots in Eppendorf tubes 
at -80°C. 
2.2.6.2 Agrobacterium transformation  
Aliquots containing 2.5 µg of recombinant pGreen-35S-mPrP plasmid and 2 µg 
of the pSoup plasmid was added to 50 µl of electrocompetent AGL1 cells and 
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mixed. The mixture was transferred to a 2 mm electroporation cuvette and 
electroporated with the MicroPulser Electroporator (Bio-Rad). Aliquots of 0.95 ml 
YEP broth was added to the electroporated cells and the mixture incubated at 
28°C for 4 hours in an Eppendorf thermomixer at 100 rpm to induce expression 
of the plasmid’s antibiotic-resistance gene. Subsequently, the transformed cells 
were pelleted by centrifugation at 13,000 rpm for 1 minute and resuspended in 
200 µl YEP broth. Aliquots of 50 µl of the suspension was spread on kanamycin 
(100 µg/ml) YEP plates (1 Litre: YEP broth and 15 g Agar). The YEP plates were 
incubated at 28°C for three days.  Transformed AGL1 colonies were identified by 
antibiotic resistance and plasmids isolated and characterised by restriction 
enzyme analysis (Sections 2.2.5.1, 2.2.5.2 and 2.2.5.6). 
2.2.6.3 Tobacco leaves transformation  
Leaf disks were excised from axenic tobacco plants using a sterilised Eppendorf 
Snap Cap (Fisher Scientific).  The leaf disks (explants) were transformed as 
described by Horsch et al. (1989). Transformed AGL1 cells were grown in 10 ml 
of YEP broth containing kanamycin (100 µg/ml) in an orbital shaker at 250 rpm 
till log phase. The cells were centrifuged at 5,000 rpm for 10 minutes and the 
pellets washed twice with 10 ml ice cold MS broth (1 Litre: 4.4 g Murashige and 
Skoog basal medium and 30 g sucrose) (Murashige and Skoog, 1962). 
Subsequently, the cells were resuspended in MS broth at an optical density 
(OD600) of 0.4.  
Sterile leaf disks were immersed in 25 ml Agrobacterium suspension in a petri 
dish. After 30 minutes, the explants were blotted on sterile filter paper and 
transferred to MS plates (1 Litre: MS broth and 8.8 g Plant agar). The plates were 
sealed and kept in the dark for three day for callus induction. The explants were 
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transferred to MS plates containing plant growth hormones (1 Litre: 2 mg BAP 
and 0.2 mg NAA) and antibiotics, kanamycin (100 µg/ml), cefotaxime (500 µg/ml), 
carbenicillin (500 µg/ml), and incubated at 25°C on a 16 hour photoperiod. A 10-
fold difference in cytokinin to auxin ratio is required for maximum callus formation 
(Ali et al., 2007; Barendse et al., 1987).  Shoot regeneration occurred after about 
6 weeks. The shoots were excised and transferred to Phytatray(s) II containing 
MS media and kanamycin (100 µg/ml) for root induction and selection of 
transgenic plants.   
2.3 Characterisation of recombinant mPrP in transgenic tobacco leaves  
2.3.1 DNA analysis 
2.3.1.1 Polymerase chain reaction (PCR) 
Healthy and fully extended transgenic plant leaves (100 mg) frozen in liquid 
nitrogen was homogenised in an Eppendorf tube with a micropestle. Genomic 
DNA was isolated from the leaves of transgenic tobacco plants using a DNeasy 
Plant mini kit (Qiagen). PCR amplification of 100 ng of genomic DNA was 
performed with the iProof high-fidelity Master Mix kit (Bio-Rad) using 0.2 µM of 
each mPrP primer (Table 2.1) specific for the synthetic transgene. The reaction 
was carried out on the T100 Thermal Cycler (Qiagen) under the following 
conditions: Initial denaturation for three minutes at 98°C, 30 cycles with the 
temperature sequence (98°C for 10 seconds, 58°C for 20 seconds and 72°C for 
15 seconds) and final elongation at 72°C for 5 minutes. Afterwards, PCR products 
were analysed by electrophoresis on 2% agarose gels. 
35 
 
2.3.2 RNA analysis 
2.3.2.1  Reverse transcription (RT)-PCR  
Total RNA was extracted from homogenised transgenic tobacco leaves with the 
RNeasy Plant mini kit (Qiagen). To remove DNA contamination, the RNA was 
treated with RNase-free DNase (Qiagen) during the isolation procedure then the 
purity of the RNA was determined using the Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific). RT-PCR reactions were 
performed in two steps. Firstly, cDNA was synthesised from 0.5 µg of isolated 
RNA, using the iScript reverse transcription Supermix (Bio-Rad). Secondly, cDNA 
was subjected to PCR using the conditions described in section 2.3.1.1. 
2.3.2.2 Real time RT-PCR  
RNA expression levels were quantified using real time PCR as described by Pfaffl 
(2001). After cDNA synthesis, real-time amplification of the samples was 
performed using the SsoAdvanced Universal SYBR Green Supermix kit (Bio-
Rad). The Elongation factor 1α gene (EF1α) was used as an internal reference 
gene (Schmidt and Delaney, 2010). cDNA (50 ng) and either the PrP or EF1 
primers (0.25 µM each) (Table 2.1) were added the reaction mix. The reaction 
was carried out in replicates on the Stratagene Mx3000P QPCR System (Agilent 
Technologies) under the following conditions: Initial denaturation for two minutes 
at 98°C, 40 cycles with the temperature sequence (Denaturation: 95°C for 10 
seconds; Annealing/Extension: 60°C for 30 seconds). At the end of the reaction 
a melt curve analysis was carried out to ensure the efficiency of the primers. 
To create a standard curve to determine efficiency of the reaction, serial dilutions 
of PCR amplified cDNA products of both the PrP and the EF1 primers were 
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analysed by real time PCR. Quantitative RT-PCR calculations are shown in 
Appendix F. 
Primer Sequence Amplicon 
Size (bp) 
CaMV 
(Sequencing) 
        Forward: ACGCACAATCCCACTATCC 
        Reverse: GCGAAACCCTATAAGAACCC 
Varied 
EF1         Forward: AATGGGTGCTTCAGCTTTAC 
        Reverse: AGCATATCCATTGCCAATCT 
72 
PrP         Forward: AACCAATGGAACAAACCATC 
        Reverse: AAGTCCTCCAACAACAGCTC 
87 
mPrP         Forward: ATGTTGGGATCTGCAATGTC 
        Reverse: CTGTTCAACAACTCTCTCCATC 
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2.3.3 Protein Analysis 
2.3.3.1  Western blot 
Homogenised transgenic tobacco leaves (100 mg) were resuspended in 200 µl 
of 2X Laemmli sample buffer (Bio-Rad). The solution was incubated at 90°C for 
10 minutes and centrifuged. The clarified lysate (20 µl) was electrophoresed on 
a 12% Mini-PROTEAN TGX precast gel (Bio-Rad) at 200 volts for 40 minutes. 
Subsequently, the separated proteins were transferred to a nitrocellulose 
membrane using the Trans-Blot turbo system (Bio-Rad). The membrane was 
Table 2.1: Primer Sequences 
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blocked with 5% powdered milk in TBS buffer (20mM Tris, 500mM NaCl, pH 7.5), 
incubated overnight in a 1:2,500 dilution of either the horse radish peroxide (HRP) 
conjugated anti-6X His-tag antibody (Abcam) or 1:1000 dilution of the PrP 
polyclonal antibody C-20 (Santa Cruz Biotechnology)  in blocking solution.  The 
C-20-probed membrane was washed three times in TBST buffer (TBS, 0.05% 
Tween-20) for 5 minutes each then incubated in a 1:2000 dilution of HRP-
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology) in blocking solution 
and washed three times in TBST buffer and once with TBS. The anti-6X His-tag 
antibody-probed membrane was washed five times in TBST buffer and once with 
TBS. Subsequently, blots were developed with the ECL chemiluminescent 
reagent (Bio-Rad) prior to chemiluminescent imaging on the ChemiDoc MP 
Imaging System (Bio-Rad). 
2.3.3.2 Enzyme-linked immunosorbent assay (ELISA) 
PRNP standards (10 ng/ml, 5 ng/ml, 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, 0.312 
ng/ml, 0.156 ng/ul and a blank solution 0 ng/ml made up with standard diluent 
only) were prepared by serial dilution from the standard stock solution (20 ng/ml). 
Healthy and fully expanded tobacco leaves (100 mg) were homogenised and 
solubilised in 250 µl of PBST buffer (1 litre: 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 
0.24 g KH2PO4  and 1% Triton X-100). The solution was clarified by centrifugation 
and the clarified lysate used for the protein assay. 100 µl of the standards, 
transformed and untransformed plant lysate samples were added to 
predetermined wells on a 96 well plate, the plates were sealed and incubated at 
37°C for 2 hours. Afterwards, the solution was removed from each well using an 
aspirator and 100 µl of detection reagent A was added to the wells and the plates 
were sealed and incubated for 1 hour at 37°C.Then the solution was aspirated 
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and wash solution was added to the wells and allowed to sit for 2 mins then 
aspirated. This process was repeated thrice before 100 µl of detection reagent B 
was added to the wells and the plates sealed and incubated for 30 minutes at 
37°C. The wells were washed 5 times as described above and 90 µl of 
Tetramethylbenzidine (TMB) substrate was added to the wells and the plate 
covered and incubated for 15 minutes at 37°C. 50 µl of the stop solution was then 
added to the wells and absorbance measured immediately at 450 nm on a 
Thermomultiskan microplate reader (Thermo Fisher Scientific). To calculate the  
recombinant mPrP concentration in the plant samples analysed an average of 
the duplicate reading for each standard was determined and the average optical 
density (O.D.) of the blank standard was subtracted and a standard curve created 
by plotting the O.D. of the standards against the concentration of the standards. 
To account for background, the O.D. of the untransformed plant sample was 
subtracted from the O.D. of the transgenic plant samples analysed and the 
recombinant mPrP concentration was determined from the standard curve. 
2.3.3.3 Bradford Assay 
 
Bovine serum albumin (BSA) protein standards (1.5 mg/ml, 1.0 mg/ml, 0.75 
mg/ml, 0.5 mg/ml, 0.375 mg/ml, 0.25 mg/ml and 0 mg/ml, the blank which 
contained only distilled water) were added to 96 well plate. The tobacco leave 
lysate samples were diluted 10-fold with distilled water. For the assay, 5 µl of the 
protein standards and the plant samples were added to predetermined wells of a 
96 well plate then 250 µl of the Bradford reagent was added to the wells used 
and the plate mixed on a shaker for 30 secs. The samples were incubated at 
room temperature for 10 mins and absorbance measured at 595nm. The soluble 
protein concentration of the plant samples was determined from the BSA 
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standard curve. The mPrP concentration in the plant samples was expressed as 
a percentage of the total soluble protein concentration as shown in Appendix E. 
Chemical analysis of transgenic tobacco leaves  
2.3.4 Analysis of Plant Nutrients 
Healthy fully expanded leaves from 30 day old transgenic tobacco plants, grown 
on MS media only or with kanamycin (100 µg/ml) included in the media, were 
excised and mailed in an antistatic package to the Alice Holt forest research 
institute where the samples were analysed for macro elements (Nitrogen, 
Phosphorus, Potassium, Calcium and Magnesium) and micro elements (Iron, 
Manganese, Copper, Boron, Nickel and Zinc).  
The leaves were dried and homogenised using a mill (Cyclotec). The 
homogenate was re-dried at ~70°C for 8 hours or overnight to remove any 
residual moisture content. 100 mg of the homogenised leaves were digested with 
1 ml of concentrated sulphuric acid in a 15 ml borosilicate or quartz tube. Then 
two doses of 30% hydrogen peroxide (0.4 ml) was added to the mixture. The 
tubes were then heated at 335°C for 30 minutes. Afterwards an additional dose 
of hydrogen peroxide was added to the solution and placed on the heating block 
for another 10 minutes. The process was repeated until the digests were clear. 
The samples were made up to 15 ml with distilled water and analysed for metal 
content on a dual view inductively coupled plasma optical emission spectrometry 
(ICP-OES) (THERMODROP 6500). The total nitrogen content of the re-dried 
homogenate was analysed using reference method ISO 13878. All results are 
expressed based on the dry weight of the plant samples. 
40 
 
2.3.5 Peroxidase Assay 
Leaves from 30 day old transgenic plants (10 mg), grown either on MS media 
only or with kanamycin (100 µg/ml) included in the media, were homogenised in 
200 µl of Assay Buffer.  The clarified lysate (50 µl) was analysed for peroxidase 
activity using the peroxidase activity assay kit (Sigma-Aldrich). Absorbance was 
measured at 570 nm on a Thermo Multiskan microplate reader (Thermo Fisher 
Scientific) at 3 minutes intervals. Peroxidase activity was calculated from the 
initial and penultimate spectrophotometer readings using the manufacturer’s 
protocol.   
Statistical analysis  
The effect of the expression of heterologous mPrP on plants nutrients was 
analysed by two-way analysis of variance (ANOVA) and Bonferroni post hoc 
analysis.  
2.4 Purification of recombinant mPrP 
 
2.4.1 Lysis buffers  
The buffer component of the various lysis buffers are shown in Table 2.2 and 
properties of detergents used in Table 2.3. 
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Buffer Components 
A 50 mM Tris-HCl, 500 mM NaCl, 2 mM PMSF and 8 M urea 
B 20 mM Sodium phosphate, 500 mM NaCl, 2 mM PMSF and 1% 
Triton X-100 
C 50 mM HEPES, 500 mM NaCl, 2 mM PMSF, 1% Triton X-100 and 
8M urea 
D 50 mM HEPES, 150 mM NaCl, 2 mM PMSF, 1% Triton X-100, 30 
mM 2-Mercaptoethanol and 8M urea 
E 50 mM HEPES, 10 mM NaCl, 2 mM PMSF, 1% Triton X-100, 30 mM  
2-Mercaptoethanol and 8M urea 
F 50 mM HEPES, 500 mM NaCl, 2 mM PMSF, 2% CHAPS , 30 mM  
2-Mercaptoethanol and 8M urea 
 
 
 
 
 
 
 
 
 
Table 2.2: Tobacco leaf protein extraction buffers 
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2.4.2 Sample Preparation  
Transgenic tobacco leaves from healthy plants (10 g) was homogenised in 
various lysis buffer listed in Table 2.2 in the presence of EDTA-free protease 
inhibitor tablets (Thermo Fisher Scientific). Plant to lysis buffer ratio were varied 
to determine optimal concentration for the purification process. The various 
lysates were clarified by centrifugation at 20, 000 rpm for 30 minutes.  
Detergent Triton X-100 CHAPS 
Structure 
  
Type Non-ionic Zwitterionic 
MW monomer 647 615 
MW micelle 90000 6000 
CMC  mM 
(%w/v) 
0.24 
(0.0155) 
8-10 
(0.5-0.6) 
Aggregation No 140 10 
Cloud Point °C 64 >100 
Dialyzable No Yes 
Table 2.3: Properties of detergents used in lysis buffer 
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2.4.3 Purification  
Recombinant mPrP was isolated from the clarified lysate by immobilised metal 
affinity-chromatography (IMAC) using either the 1 ml HiTrap Chelating HP 
columns loaded with either Nickel or Cobalt ions (GE Healthcare Life Sciences) 
or the His GraviTrap TALON columns precharged with Co2+ ions (GE Healthcare 
Life Sciences). The HiTrap column is advantageous for optimising the purification 
process and choice of metal ion while the GraviTrap column offers advantages in 
terms of convenience, binding capacity (15 mg/column), binding affinity and 
ability to run large sample volumes. After the lysate was passed through the 
columns, the flow-through was collected then the column was washed with 10X 
lysate volume of wash buffer (lysis buffer (without detergent and protease 
inhibitor) + 5 mM imidazole) and the wash fraction collected. The recombinant 
protein was eluted in 500 µl fractions with elution buffer (Lysis buffer without 
detergent + 300 mM imidazole). Afterwards the various fractions were mixed with 
2X Laemmli sample buffer in a 1:3 ratio and analysed by western blot as 
described in section 2.3.3.1. 
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3 Design of Transgene Constructs 
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3.1 Introduction 
Prion diseases are a group of neurodegenerative diseases that affect mammals, 
transmitted by an infectious protein called prion (Prusiner, 1998). Post-
translational changes in the structure of PrPC converts it to PrPSc. The various 
PrPSc isoforms differ in their sensitivity to proteases, solubility and cellular 
distribution (Prusiner, 1998; Harris, 1999). The molecular mechanism underlying 
the conversion to the aberrant isoform is poorly understood. Problems with 
adequate yields from the purification of PrPC from brain homogenates and 
insolubility of the infectious isoform has prevented the advancement of research 
in this area. Although, recombinant mPrP has been produced in bacteria 
(Hornemann et al., 1997), bacteria expression systems do not have the capacity 
for post-translational modification. Hence, production of recombinant mPrP in 
plant expression systems, which offer post-translational modification, may help 
researchers elucidate the process of PrPC to PrPSc conversion and understand 
PrPSc neurotoxicity. 
To address the possibility of plant expression systems producing recombinant 
mPrP, a synthetic mouse PRNP gene for heterologous expression in tobacco 
plants was designed. The choice of tobacco plant was based on convenience 
due to the availability of established transformation protocols for recombinant 
protein production. Research to improve recombinant protein production and 
stability in plants has established that the rate of transcription and translation may 
be improved by adding regulatory elements and modifying codon usage of the 
transgene. Furthermore, protein stability may be enhanced by adding sequences 
conserved for subcellular localisation to the transgene construct (Birch, 1997; 
Sharma and Sharma, 2009). 
46 
 
3.2 Results  
3.2.1 Synthetic mPrP gene constructs 
The DNA sequence of the mature peptide of the mouse PRNP gene (GenBank 
ID: NM_011170.2) was optimised for expression in tobacco. Using GENEius 
software (Eurofins MWG Operon), the codon usage of mouse PRNP gene was 
changed to reflect the preferred codons of tobacco nuclear genes (Figure 3.1). 
Alignment of the synthetic and native gene gave a sequence similarity of 74%. 
As shown in Figure 3.2, altering the codon improved the codon adaptation index 
from 0.68 to 0.92 and reduced the GC content from 60.21% to 44.80%. 
 
Figure 3.1: Creation of a synthetic mPrP gene for expression in tobacco plants 
Sequence alignment of the native mPrP gene and the synthetic gene. Altered 
nucleotides are coloured. Image design: Geneious Software Version 9.1.5 
(http://www.geneious.com, Kearse et al., 2012) 
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Several regulatory elements were added to the synthetic mouse PRNP gene 
sequence of all three constructs, mPrP-Cyto (Figure 3.4), mPrP-Apo (Figure 3.5) 
and mPrP-ER (Figure 3.6). Restriction sites  for BamHI and EcoRI were added 
for subcloning purposes, a C-terminal hexahistidine-tag for affinity purification 
and the translation enhancers, TMV omega sequence (GenBank ID: M24955.1) 
and 3’ UTR TMV (GenBank ID: V01406.1:801-1004). Also, the signal peptide of 
Figure 3.2: Comparative codon analysis of native mouse prion protein and 
synthetic mouse prion protein optimised for expression in Nicotiana Tabacum. 
Nucleotide alterations increased the CAI from 0.68 to 0.92 and decreased the % GC 
content from 60.21 to 44.80. Analysis: GenScript Rare Codon Analysis Tool 
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PR1a of tobacco (GenBank ID: X06361.1) was added to the apoplast and ER 
constructs for subcellular localisation. Finally, the  “SEKDEL” ER retrieval 
sequence was added to the ER constructs for ER retention of the recominant 
protein. All constructs were synthesised and cloned into pEX-A plasmid (Eurofins 
MWG Operon).  
 
 
A 
 
B 
 
C 
 
Figure 3.3: Schematic representation of mPrP transgene constructs. A: mPrP-
Cyto (933 bp). B: mPrP-Apo (1029 bp). C: mPrP-ER (1047 bp). Image design: 
SnapGene Software Version 1.5.3 (GSL Biotech). 
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Figure 3.4: Annotated mPrP-Cyto nucleotide sequence. Features: restriction sites 
BamHI and EcoRI, (5’UTR and 3’UTR) TMV, location of mPrP primer site for PCR 
analysis and polyhistidine-tag. Image Design: Geneious Software Version 9.1.5 
(http://www.geneious.com, Kearse et al., 2012). 
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Figure 3.5: Annotated mPrP-Apo nucleotide sequence. Features: restriction sites 
BamHI and EcoRI, (5’UTR and 3’UTR) TMV, location of mPrP primer site for PCR 
analysis, polyhistidine-tag and PR1a signal peptide. Image Design: Geneious 
Software Version 9.1.5 (http://www.geneious.com, Kearse et al., 2012). 
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Figure 3.6: Annotated mPrP-ER nucleotide sequence. Features: restriction sites 
BamHI and EcoRI, (5’UTR and 3’UTR) TMV, PR1a signal peptide, location of mPrP 
primer site for PCR analysis, polyhistidine-tag and ER retrieval sequence. Image 
Design: Geneious Software Version 9.1.5 (http://www.geneious.com, Kearse et al., 
2012). 
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3.2.2 Plant Expression Vectors  
3.2.2.1 p35S-2-mPrP cassettes 
The mPrP constructs, mPrP-Cyto (0.9 kb), mPrP-Apo (1.0 kb) and mPrP-ER (1.0 
kb), were excised from pEX-A with BamHI and EcoRI restriction enzymes and 
inserted into the p35S-2 cassette (Hellens et al., 2000) also digested with BamHI 
and EcoRI. All digested fragments were ligated using Lyo-Ligase (Bioline) to 
generate p35S-2-mPrP-Cyto, p35S-2-mPrP-Apo and p35S-2-mPrP-ER. 
Subsequently, the modified p35S-2 constructs were transformed into E. coli 
DH5α cells and positive clones were identified by their growth on ampicillin LB 
plates. The p35S-2-mPrP recombinant plasmids were purified from positive 
colonies using a plasmid miniprep protocol (Qiagen). Restriction analysis of the 
isolated plasmids (Figure 3.7) using EcoRV produced two fragments, a 2.2 kb 
vector backbone and either 35S-mPrP-Cyto (1.58 kb), 35S-mPrP-Apo (1.66 kb) 
or 35S-mPrP-ER (1.68 kb). The results confirmed the integrity of the recombinant 
p35S-2-mPrP constructs. 
 
 
 
 
 
  
Figure 3.7: EcoRV analysis of p35S-2-mPrP constructs. Lane 1: Molecular Weight 
Marker. Lane 2: p35S-2. Lane 3: p35S-2-mPrP-Cyto. Lane 4: p35S-2-mPrP-Apo. 
Lane 5: p35S-2-mPrP-ER. 
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Figure 3.8: Schematic representation of p35S-2-mPrP transgene cassettes. A: 
35S-mPrP-Cyto, 1.58 kb. B: 35S-mPrP-Apo, 1.66 kb. C: 35S-mprp-ER, 1.68 kb. 
Image design: SnapGene Software Version 1.5.3 (GSL Biotech). 
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3.2.2.2 pGreen-35S-mPrP cassettes 
The p35S-2-mPrP cassettes were excised with restriction enzyme EcoRV and 
each insert ligated into a pGreen0029 vector (Hellens et al., 2000) also digested 
with EcoRV, using Lyo-ligase (Bioline).  The resultant pGreen-35S-mPrP 
recombinant plasmids were transformed into E. coli DH5α cells and positive 
clones were identified by their growth on kanamycin LB plates. Subsequently, 
plasmids were isolated by miniprep (Qiagen) and digested with EcoRV for 
analysis. As shown in Figure 3.9, restriction analysis of the constructs produced 
two fragments, a 4.6 kb vector backbone and either pGreen-35S-mPrP-Cyto 
(1.58 kb), pGreen-35S-mPrP-Apo (1.66 kb) or pGreen-35S-mPrP-ER (1.68 kb). 
The lower molecular weight bands present in lane 2, figure 3.9 are thought to be 
due to star activity of EcoRV. The results indicate the integrity of the recombinant 
pGreen-35S-mPrP plasmids (Figures 3.10 - 3.12). Results were confirmed by 
sequence analysis. The recombinant pGreen-35S-mPrP plasmids obtained were 
suitable for Agrobacterium tumefaciens-mediated plant transformation. 
 
  
Figure 3.9: EcoRV Analysis of pGreen-35S-mPrP constructs. Lane 1: Molecular 
Weight Marker. Lane 2: pGreen. Lane 3: p35S-2mPrPCyto. Lane 4: p35S-2mPrPApo. 
Lane 5: p35S-2mPrPER. 
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Figure 3.10: Schematic representation of pGreen-35S-mPrP-Cyto plasmid.  
The 35S-mPrP-Cyto cassette forms a 1.58 kb insert between the EcoRV sites at 1075 
bp and 2653 bp. Image design: SnapGene Software Version 1.5.3 (GSL Biotech) 
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Figure 3.11: Schematic representation of pGreen-35S-mPrP-Apo plasmid. The 
35S-mPrP-Apo cassette forms a 1.66 kb insert between the EcoRV sites at 1075 bp 
and 2740 bp   Image design: SnapGene Software Version 1.5.3 (GSL Biotech) 
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Figure 3.12: Schematic representation of pGreen-35S-mPrP-ER plasmid. The 
35S-mPrP-ER cassette forms a 1.68 kb insert between the EcoRV sites at 1075 bp 
and 2758 bp   Image design: SnapGene Software Version 1.5.3 (GSL Biotech) 
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3.2.3 Plant Transformation  
Tobacco plants were transformed by Agrobacterium (Horsch, 1985), based on its 
ability to integrate the recombinant T-DNA (Figure 3.14) into the plant’s nuclear 
genome.  The plant expression constructs were each transformed into 
Agrobacterium tumenfaciens cells alongside the helper plasmid pSoup by 
electroporation. Positive clones were identified by growth on kanamycin YEP 
plates. Subsequently, leaf discs from axenic tobacco plants were infected with 
Agrobacterium suspension that contained the pGreen-35S-mPrP-Cyto, pGreen-
35S-mPrP-Apo or pGreen-35S-mPrP-ER recombinant plasmid. The explants 
were cocultured with Agrobacterium in the dark for three days on MS media for 
callus induction and transferred to kanamycin MS media for selection of putative 
transgenic shoots (Section 2.2.6.3).  
 
 
Figure 3.9 EcoRV analysis of pGreenn35SmPrP constructs. Lanes: 1) Molecular 
Weight Marker 2) pGreen 3) 35S-mPrP-Cyto 4) 35S-mPrP-Apo 5) 35S—mPrP-ER. 
Figure 3.13: Stages in Plant Transformation. A: Excision of Tobacco Leaf discs 
(Explants). B: Inoculation of explants with Agrobacterium. C: Coculturing of explants 
with Agrobacterium. D: Callus on kanamycin MS media. E: Shoot regeneration. F: 
Mature transgenic shoots. 
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Figure 3.14: Schematic representation of recombinant T-DNA region of 
constructs A: pGreen-35S-mPrP-Cyto. B: pGreen-35S-mPrP-Apo. C: pGreen-35S-
mPrP-ER. Image design: SnapGene 
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3.3 Discussion 
Plants are a conventional heterologous expression system for the production of 
recombinant proteins. The quality and yield of plant-expressed recombinant 
protein depends considerably on the design of an effective transgene expression 
cassette (Ma et al., 2003; Ullrich et al., 2015).  In plant expression systems 
recombinant protein yields may be low because of codon bias. Codon usage bias 
is the event that a given species prefers using a particular codon to other 
synonymous codons during gene translation (Hershberg and Petrov, 2008). 
Protein expression levels are influenced by codon bias, as they reflect the tRNA 
levels in the expression system (Gustafsson et al., 2004; Ullrich et al., 2015). For 
instance, if the recombinant protein being expressed contains a high frequency 
of a codon less frequently used in the host plant, the tRNA pool will be exhausted 
leading to low expression of the recombinant protein. Therefore, the nucleotide 
sequences of transgenes are usually altered, using codon bias tables and gene 
optimisation software, to reflect the codon usage of the host organism. In this 
study, to create the recombinant mouse prion gene suitable for expression in 
tobacco we modified 50% of the codons of mPrP to reflect the codon bias of 
Nicotiana tabacum using the GENEius software. The effect of this modification 
was measured by CAI and %GC content. The probability of high protein 
expression level correlates with the value of the codon adaptation index (Sharp 
et al., 1987).  Optimising the mouse prion gene increased CAI to 0.92 which is 
above the 0.8 threshold for good gene expression in a heterologous system. Also, 
the synthetic gene had a reduced GC content of 44.8% which is analogous to the 
43.38% GC content of tobacco nuclear genes.  
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The addition of regulatory elements to a transgene construct usually enhances 
the rates of transcription and translation. Promoters are important regulatory 
elements that direct the transcription rate of transgenes. The CaMV 35S promoter 
is a strong constitutive promoter mostly effective for stable nuclear transformation 
(Odell et al., 1985). Studies have shown that the CaMV 35S confers the highest 
expression level of transgenes in dicotyledonous plants, hence, its extensive use 
in plant expression systems (Fang et al.,1989; Comai et al., 1990). Almost 80% 
of transgenes expressed in plants are driven by the CaMV 35S promoter (Hull et 
al., 2000). In addition to codon optimisation, translational efficiency of 
heterologous genes is significantly improved by including the 5’ and 3’ 
untranslated regions of plant viral mRNAs in the transgene construct.  The 5’ UTR 
and 3’ UTR of TMV enhances translation of transgenes independently. The 
5’UTR of TMV acts as a binding site for the translational enhancer, heat shock 
protein HSP101 (Gallie, 2002).  The 3’ UTR of TMV increases mRNA stability 
and translation. Studies have shown adding the 3’UTR of TMV to foreign gene 
constructs may increases transgene expression by 100-fold (Gallie and Walboth, 
1990). Ideally, improved transcription and translation should increase 
recombinant protein levels. However, this rarely correlates with protein levels due 
to degradation of protein by proteases in the host system (Conrad and Fiedler, 
1998). 
Plant recombinant protein levels are affected by their subcellular location 
(Egelkrout, 2012).  In the absence of targeting signals most recombinant proteins 
are directed to the cytosol. Cytosolic proteins typically have no post-translational 
modification and are quickly degraded by abundant proteases present in the 
cytosol. Addition of an N-terminal signal peptide to the recombinant protein 
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normally directs the recombinant protein to the apoplast. Proteins in the apoplast 
are post-translationally modified in the endoplasmic reticulum and the Golgi 
apparatus (Stoger et al., 2005). The N-terminal signal sequence of the 
pathogenesis related protein (PR1a) of tobacco has been successfully used to 
direct recombinant proteins to the apoplast of tobacco plants (Pen et al., 1992). 
Also, recombinant protein levels are significantly improved due to depleted 
protease activity in the apoplast. Alternatively, the protein may be retained in the 
endoplasmic reticulum by addition of the SEKDEL ER retrieval sequence (Munro 
and Pelham, 1987) to the transgene construct. The ER has lower protease 
activity than both the cytosol and the apoplast (Egelkrout, 2012). Also, 
recombinant proteins in the ER lack complex plant glycans that cause 
immunogenicity, hence, it is the favoured location for recombinant proteins. 
However, it is important to note that since proteins are distinct, accumulation 
levels of a particular protein in different subcellular compartments can only be 
determined directly by experimentation.  
Purification of recombinant protein is essential for biochemical and biophysical 
characterisation of the protein. A standard purification strategy involves fusing the 
recombinant protein to a peptide affinity tag followed by affinity chromatography 
purification, usually in a single step process (Bornhorst and Falke, 2000). The 
polyhistidine affinity tag, utilising its affinity to immobilised metal ion in 
immobilised metal affinity chromatography (IMAC), is the most studied affinity tag 
for protein purification. Therefore, it is a good choice for a novel purification 
attempt of a heterologously expressed protein. Additionally, polyhistidine-tagged 
recombinant mPrP has been successfully purified from E.coli and the peptide tag 
had no effect on the quality of the protein (Hornemann et al., 1997). Examples of 
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histidine-tagged recombinant protein purified from tobacco includes recombinant 
interferon gamma (Leelavathi and Reddy, 2003) and recombinant HIV-Nef 
antigen (Marusic et al., 2007) 
Agrobacterium has the ability to integrate its T-DNA into the plant nuclear 
genome. This involves a complex mechanism where wounded plants secrete low 
molecular weight compounds such as acetosyringone that are recognised by 
Agrobacterium as a signal to instigate expression of virulence genes and initiate 
transfer of T-DNA into the plant nuclear genome (Gelvin, 2003). Transgenes 
which require post-translational modifications are best transformed via 
Agrobacterium because they are integrated into the plant nuclear genome (Ma et 
al., 2003). Stable integration of T-DNA into the plant genome is influenced by 
factors such as time, density of Agrobacterium suspension, light and length of 
cocultivation. For instance, Agrobacterium suspensions with an optical density 
above 0.5 usually causes necrosis of explants (Binns, 2002) while light impedes 
motility of Agrobacterium (Oberpichler et al., 2008). Plant transformation via 
Agrobacterium offers significant advantages over other documented methods 
including ease, affordability, established protocols, high transformation efficiency, 
low transgene copy number and stable integration of the transgene (Binns, 2002). 
Years of plant biotechnology research has elucidated various approaches to 
enhance recombinant protein yield in transgenic plants. Several of the strategies 
described in previous paragraphs, were used to create three transgene 
constructs pGreen-35S-mPrP-Cyto, pGreen-35S-mPrP-Apo and pGreen-35S-
mPrP-ER for enhanced production of recombinant mPrP in tobacco plants. 
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4 Characterisation of recombinant mPrP in 
transgenic tobacco leaves 
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4.1 Introduction 
Proteins are complex biological molecules that self-assemble into adaptable 
three dimensional structures. The most thermodynamically stable conformation 
of a protein under physiological conditions is known as its native structure.  The 
native structure of a protein determines its function while its intermediate structure 
determines cellular transport and trafficking, regulation of its biological activity 
and interaction with other molecules and its environment (Dobson et al., 2003; 
Gaggelli et al., 2006). The tertiary structure of a protein is encoded by its amino 
acid sequence. Therefore, mutations affecting the amino acid sequence may 
cause genetic disorders which are frequently characterised by pathogenic 
misfolded protein aggregates (Dobson et al., 2003). However, evidence shows 
that changes in physiological conditions can also alter the conformation of most 
proteins (Soto, 2003). 
Protein conformational disorders occur when a protein deviates from its native 
structure and maintains a stable alternate conformation by aggregation and 
accumulation into amyloid fibrils (Soto, 2003; Chiti and Dobson, 2006; Brundin et 
al., 2010). Neurodegenerative diseases such as Alzheimer’s, prion and 
Parkinson’s diseases are protein conformational disorders that affect the brain. 
Evidence has shown that the aforementioned neurodegenerative diseases may 
share a common pathogenic mechanism due to similar features. Firstly, 
neurodegenerative diseases are late onset possibly due to increased oxidative 
stress and change in metal homeostasis (Sayre et al., 2000; Gaggelli et al., 
2006). Secondly, they are mostly sporadic with genetic mutation accounting for 
only 20% of cases (Prusiner, 2001). Thirdly, they share similar pathological 
symptoms including misfolded protein deposits that bind amyloid specific dyes, 
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neuronal loss and abnormal synaptic function (Soto, 2003; Chiti and Dobson, 
2006). Finally, structural studies have shown that the misfolded protein 
aggregates are created via a nucleation mechanism and characterised by soluble 
oligomeric intermediates and β-sheet rich fibrils (Dobson et al., 2003; Ross and 
Poirier, 2004). However, the distinct clinical symptoms exhibited by each 
neurodegenerative disease is determined by the specific protein, brain region and 
class of neurons affected (Dobson et al., 2003; Soto, 2003). 
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4.2 Results  
Regenerated shoots were obtained from tobacco calli transformed with either the 
pGreen-35S-mPrP-Cyto or pGreen-35S-mPrP-ER construct, as shown in table 
4.1. Unfortunately, all explants transformed with the pGreen-35S-mPrP-Apo 
construct were lost to contamination even though the experiment was repeated 
thrice. Putative transformants from the surviving constructs were selected by 
subculturing on kanamycin-treated MS media. Five randomly chosen transgenic 
plants from each construct were characterised for transgene integration and 
mRNA transcription levels. The accumulation of recombinant mPrP from both 
constructs were determined by ELISA assay. 
 
Table 4.1: Transformation efficiency of tobacco explants 
Transgene 
Construct 
Inoculated 
Explants 
Kanamycin  
Resistant 
Shoots 
Transformation 
Efficiency (%) 
pGreen-35S-
mPrP-Cyto 
150 23 15.33 
pGreen-35S-
mPrP-ER 
150 10 6.6 
pGreen-35S-
mPrP-Apo 
150 0 0.00 
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4.2.1 Analysis of transgenic plants expressing cytosolic-mPrP 
 Integration of mPrP transgene into the nuclear genome of plants transformed 
with the pGreen-35S-mPrP-Cyto construct was determined by PCR-screening of 
DNA from putative transformants (Figure 4.1). The mPrP primers designed from 
the synthetic mouse prion gene generated a 250 bp product in transformants 
while the control plant transformed with the pGreen vector showed no PCR 
product. The result confirms stable integration of the synthetic PRNP gene in the 
five transgenic lines tested.   
 
 
Expression of recombinant mPrP was determined by RT-PCR analysis (Figure 
4.2) and measured by qRT-PCR analysis with transgenic line C4 used as 
calibrator (Figure 4.3). PRNP transcripts of size 250 bp were detected from PCR 
analysis of cDNA from the transgenic lines tested while no transcript was 
detected in cDNA from a pGreen transgenic plant used as a control (Figure 4.2). 
Figure 4.1: PCR analysis of transgenic tobacco leaves transformed with the 
pGreen-35S-mPrP-Cyto construct. M: DNA size marker, Lanes 1-5: DNA 
amplification product from transgenic lines C4, C7, C9, C12 and C15 respectively. 
Lane 6: Control – DNA amplification product from transgenic tobacco leaves 
transformed with the pGreen vector. 
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The result indicates that all transgenic lines tested expressed PRNP mRNA at 
varying levels.  Transgenic line C15 had the highest expression level while C7 
had the lowest expression level.  
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Figure 4.2: RT-PCR analysis of transgenic tobacco leaves transformed with the 
pGreen-35S-mPrP-Cyto construct. M: DNA size marker. Lanes 1-5: cDNA 
amplification product from transgenic lines C4, C7, C9, C12 and C15 respectively. 
Lane 6: Control – cDNA amplification product from transgenic tobacco leaves 
transformed with the pGreen vector. 
 
Figure 4.3: qRT-PCR analysis of mPrP mRNA transcript levels in transgenic 
tobacco leaves transformed with the pGreen-35S-mPrP-Cyto construct. Data 
represents mean and standard error of the mean for triplicate measurements from 5 
independent transgenic lines.  
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Recombinant mPrP protein concentration in transgenic tobacco leaves was 
determined by ELISA analysis (Figure 4.4). The result indicates protein 
accumulation varied from 0.0004% TSP in in transgenic line C4 to 0.0024% TSP 
in transgenic line C7. Furthermore, the results show no apparent correlation 
between mPrP transcription levels and protein accumulation levels. This scenario 
is not unusual in transgenic plants since each transformation event results in a 
unique transgene location within the plant genome. The differences in mRNA 
transcription and protein translation rates, mRNA degradation rate and protein 
half-life accounts for the observed variation (Vogel and Marcotte, 2012). 
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Figure 4.4: ELISA analysis of recombinant mPrP protein concentration in 
transgenic tobacco leaves transformed with the pGreen-35S-mPrP-Cyto 
construct. Data represents mean and standard error of the mean for duplicate 
measurements from 5 independent transgenic lines.   
 
71 
 
A  
B  
 
 
Figure 4.5: Western blot analysis of transgenic tobacco leaves transformed 
with the pGreen-35S-mPrP-Cyto construct. A: Membrane probed with PrP 
antibody C-20 (1:1,000 dilution). B: Membrane probed with HRP conjugated anti 6X-
HisTag antibody (1:2,500 dilution). M: protein ladder. Lanes A6 & B6: Control – 
transgenic tobacco leaves transformed with the pGreen vector. Lane B7: 
Recombinant mPrP isolated from E.coli. Lanes A1-A5 and B1-B5: Transgenic lines 
C4, C7, C9, C12 and C15 respectively. 
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The molecular weight of the recombinant protein was determined by Western blot 
analysis using either a PrP antibody C-20 or an anti 6X His-tag antibody (Figure 
4.5). His-tag antibody had a higher affinity for the recombinant mPrP protein than 
the PrP antibody due to the presence of additional histidine residues at the C-
terminal end of the synthetic PRNP gene. His-tag antibody analysis indicated 
three bands. The ~24 kDa band indicates aglycosylated full-length mPrP while 
the ~19 kDa band represents aminoterminally truncated aglycosylated mPrP. The 
presence of the 19 kDa band when analysed with the His-tag antibody confirms 
N-terminal truncation. Finally the ~38 kDa band indicates the dimeric form of the 
truncated mPrP protein (19 kDa). Analysis with the C-20 PrP antibody indicated 
only the ~38 kDa dimer. The difference in antibody affinities accounts for the 
observed variation in the western blot assay. The results indicate effective 
production of recombinant mPrP in the cytosol of transgenic tobacco plants. 
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4.2.2 Analysis of transgenic plants transformed with the ER-mPrP 
construct 
PCR analysis of transgenic tobacco plants transformed with the pGreen-35S-
mPrP-ER construct yielded a 250 bp PCR product which confirms successful 
integration of the transgene into nuclear genome of the transgenic tobacco lines 
analysed (Figure 4.6). 
 
 
Expression levels of PRNP mRNA was established by qRT-PCR analysis (Figure 
4.8). Transgenic line E1 was used as the calibrator, the result shows variation in 
the expression levels of PRNP mRNA. Transgenic line E10 had the highest 
expression level while E2 had lowest expression level. The variation in mPrP 
mRNA transcription level can be explained by epigenetic influences of flanking 
plant DNA and the chromosomal location of the transgene (Stam et al., 1997; 
Matzke and Matzke, 1998). Also, PRNP mRNA transcripts were detected in RNA 
Figure 4.6: PCR analysis of transgenic tobacco leaves transformed with the 
pGreen-35S-mPrP-ER construct. M: DNA size marker. Lanes 1-5: DNA 
amplification product from transgenic lines E1, E2, E4, E7 and E10 respectively. Lane 
6: Control – DNA amplification product from transgenic tobacco leaves transformed 
with the pGreen vector. 
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isolated from the transgenic lines by the presence of a 250 bp amplicon after PCR 
analysis while no transcript was detected in RNA isolated from the control plant 
transformed with pGreen vector (Figure 4.7).  
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Figure 4.7: RT-PCR analysis of transgenic tobacco leaves transformed with the 
pGreen-35S-mPrP-ER construct. M: DNA size marker. Lanes 1-5: cDNA 
amplification product from transgenic lines E1, E2, E4, E7 and E10 respectively. Lane 
6: Control – cDNA amplification product from transgenic tobacco leaves transformed 
with the pGreen vector. 
 
Figure 4.8: qRT-PCR analysis of mPrP expression levels in transgenic tobacco 
leaves transformed with the pGreen-35S-mPrP-ER construct. Data represents 
mean and standard error of the mean for triplicate measurements from 5 independent 
transgenic lines.  
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Recombinant mPrP accumulation and molecular weight was determined by 
ELISA analysis (Figure 4.9) and western blot analysis (Figure 4.10) respectively. 
ELISA analysis showed variation in recombinant mPrP protein levels across the 
selected transgenic lines. Transgenic line E4 had the highest expression level at 
0.0016% TSP while E7 had the lowest expression level at 0.0003% TSP. Again, 
there was no apparent correlation between transgene expression and protein 
accumulation. Western blot detection with the His-tag antibody revealed 3 bands. 
The ~24 kDa band represents full-length unglycosylated mPrP protein, the ~31 
kDa band represents the mPrP high mannose glycoform (Figure 4.10b; lanes 4 
& 5) while the ~38 kDa band represents the dimeric form of the truncated 
unglycosylated mPrP. Comparatively, the ELISA assay result correlates with the 
result from the immunoblot analysis using the His-tag antibody. Analysis with PrP 
antibody C-20 indicated two bands after resolution, the ~38 kDa truncated dimer 
and ~31 kDa protein. The results show that various forms of the recombinant 
mPrP accumulated in transgenic plants transformed with the pGreen-35S-mPrP-
ER construct.  
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Figure 4.9: ELISA analysis of recombinant mPrP concentration in transgenic 
tobacco leaves transformed with the pGreen-35S-mPrP-ER construct. Data 
represents mean and standard error of the mean for duplicate measurements from 5 
independent transgenic lines.   
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Figure 4.10: Western blot analysis of transgenic tobacco leaves transformed 
with the pGreen-35S-mPrP-ER construct. A: Membrane probed with PrP antibody 
C-20 (1:1,000 dilution). B: Membrane probed with HRP conjugated anti 6X-HisTag 
antibody (1:2,500 dilution). M: protein ladder. Lanes A1 & B2: Control – transgenic 
tobacco leaves transformed with the pGreen vector. Lane B1: Recombinant mouse 
prion protein isolated from E.coli. Lanes A2-A6 and B3-B7: Transgenic lines E1, E2, 
E4, E7 and E10 respectively. 
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Comparative analysis of recombinant protein from both constructs is shown in 
Figure 4.11. Analysis of recombinant mPrP sequestered in the endoplasmic 
reticulum with the PrP C-20 antibody indicated two bands of ~38kDa and ~31kDa 
in lane 2 representing  the aminoterminally truncated dimer and the high mannose 
glycoform respectively while lane 1 showed only the  ~38kDa aminoterminally 
truncated dimer. 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Comparative western analysis of recombinant mPrP transformed 
with the cytosolic construct (Lane 1) and the ER construct (Lane2) using PrP 
antibody C-20 (1:1000 dilution) Lane 1: Transgenic line C23. Lane 2: Transgenic 
line E1. 
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4.3 Discussion 
The rate of cellular prion protein replication determines prion disease pathology. 
Therefore, the steps involved in PrPC biogenesis and/or degradation pathway are 
important in demystifying the mechanisms of PrPSc pathogenesis (Taraboulos et 
al., 1995; Holscher et al., 2001; Neuendorf et al., 2004; Kiachopoulos et al., 
2005). PrPC is heterogeneously synthesized in several isoforms and differentially 
expressed at varying glycoform ratios in tissues and neurons (Pan et al., 2002; 
Russelakis-Carneiro et al., 2002). As shown in figure 4.12, PrPC biosynthesis 
involves cotranslational import of the protein into the lumen of the endoplasmic 
reticulum via its N-terminal signal sequence. In the endoplasmic reticulum, the N-
terminal and C-terminal GPI signal sequences are cleaved, disulphide bond is 
formed then the GPI anchor and N-linked core glycans are added. Correctly 
folded protein matures through the secretory pathway to the Golgi where the 
glycans are processed into complex structures that are trafficked via endosomes 
to the cell surface (Heske et al., 2004; Wang et al., 2006; Rambold et al., 2006; 
Ashok and Hegde, 2008) while  mutant and misfolded  protein are sorted for 
degradation either by the ubiquitin proteasome system (UPS) of the cytosol, 
endoplasmic reticulum-associated degradation (ERAD) or post ER degradation 
via the lysosomal pathway (Ashok and Hegde, 2009).  The PrPC quality control 
pathway is complex, therefore, its dysregulation may significantly affect the 
physiology of an organism (Hegde et al., 1998). Several studies have postulated 
that age-related defects in the quality control pathway of PrPC may induce 
neurodegeneration (Russelakis-Carneiro et al., 2002; Hetz and Soto, 2006; 
Ashok and Hegde, 2009).  
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The native N-terminal signal peptide of PrPC is reported to be inefficient at 
translocating mutated PrP molecules with premature stop codon, linked to 
inherited prion diseases, to the ER compared to heterologous signal peptides 
(Holscher et al., 2001; Heske et al., 2004; Rane et al., 2010). For instance, 
increased production of CtmPrP molecules associated with GSS syndrome, was 
limited by replacing PrP signal peptide with the extremely proficient signal peptide 
of prolactin (Prl) (Rane et al., 2010). Also, Holscher et al. (2001) showed that 
mature PrP molecules with ablated N-terminal signal peptide were translocated 
to the endoplasmic reticulum via a signal sequence located in the C-terminal 
hydrophobic region of the prion protein, however, this process was inefficient and 
resulted in mainly CtmPrP molecules. In validation, Heske et al. (2004) showed 
Figure 4.12: PrP quality control pathway 
Reproduced from Aguzzi and Calella (2009)   
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that the deletion of the C-terminal hydrophobic domain interfered with import of 
PrP molecules into the ER. This implies that a regulatory element in the C-
terminal hydrophobic domain is important for efficient translocation to the 
endoplasmic reticulum, (Heske et al., 2004; Rambold et al., 2006. Norstrom et 
al., 2007; Miesbauer et al., 2010).  
The prion protein N-terminal signal sequence and the C-terminal hydrophobic 
domain work in tandem for efficient translocation of PrP molecules to the ER. 
Therefore, pathogenic mutations in either the N-terminal signal sequence or the 
C-terminal hydrophobic domain results in accumulation of PrP in the cytosol or 
increased formation of the CtmPrP transmembrane topology. The accumulation of 
PrP in the cytosol is a consolidatory feature of the neurodegenerative process in 
most prion disorders (Ma et al., 2002; Kristiansen et al., 2005; Rambold et al., 
2006; Norstrom et al., 2007) and increased synthesis of CtmPrP topological forms 
is an important marker of neurodegeneration in inherited prion diseases not 
associated with fibrillar PrPSc deposits (Hegde et al., 1999). In neurons, the 
mutations W145Stop and Q160Stop linked to GSS syndrome, are associated 
with increased presence of cytosolic PrP due to impaired ER translocation in spite 
of the N-terminal signal sequence. Also, retrograde transport of misfolded prion 
protein via the ERAD pathway results in cytosolic accumulation of PrP (Yedidia 
et al., 2001; Wang et al., 2006).  
Physiologically, cytosolic PrP is present at low levels in a subset of neurons found 
in the thalamus, hippocampus and neocortex and it protects primary neurons 
from Bax-mediated cell death (Mironov et al., 2003; Wang et al., 2006; Rambold 
et al., 2006; Westergard et al., 2007). Experimentally, overexpression of PrPC 
and proteasome inhibition causes accumulation of cytosolic PrP with similar 
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biochemical properties to PrPSc in transfected cells (Ma and Lindquist, 2001; Hetz 
and Soto, 2006; Rambold et al., 2006; Westergard et al., 2007). Furthermore, 
cytosolic PrP produced by deleting the N-terminal signal sequence and C-
terminal GPI signal sequence induced neurodegeneration in the cerebellar 
granular neurons of transgenic mice, with symptoms of prion disease including 
ataxia and gliosis (Ma et al., 2002) and induced apoptosis in human 
neuroblastoma cell lines (Rambold et al., 2006). Lastly, cytosolic PrP produced 
by inhibiting protease activity is specifically toxic to neuroblastoma cells (Ma and 
Lindquist, 2001) and cytosolic expression of recombinant PrP is toxic to yeast 
cells (Heller et al., 2003). 
Cytosolic PrP from various neuroblastoma cell lines and yeast had PrPSc-like 
properties including insolubility in non-ionic detergents, aggregation and protease 
resistance (Ma and Lindquist, 2001; Heller et al., 2003; Rambold et al., 2006; 
Norstrom et al., 2007). However, cytosolic accumulation of PrP, due to 
overexpression of PrPC is not neurotoxic (Kristiansen et al., 2005). Also, Norstrom 
et al., (2007) demonstrated that cytosolic PrP-associated neurotoxicity is 
independent of PrPSc infectivity and PrPC expression. Hypothetically, the 
neurotoxicity of cytosolic PrP has been linked to its association with the lipid core 
of membranes (Heske et al., 2004; Wang et al., 2006, Westergard et al., 2007; 
Miesbauer et al., 2010) and its interaction with the anti-apoptotic protein B-cell 
lymphoma 2 (Bcl-2) (Rambold et al., 2006).  
In this study, cytosolic-mPrP was produced in plants by adding the mature 
peptide segment (PrP23-230) of the sequence to the transgene construct. The 
expression of cytosolic-mPrP in plants either generated membrane-associated 
PrP or the cytosolic mPrP binds to membrane associated protein(s) as leaves 
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lysed without detergent yielded low intensity immunoreactive bands (Appendix D) 
compared to leaves lysed with detergent added to the buffer (Figure 4.5 & 
Appendix C). In addition, western blot analysis of the recombinant mPrP showed 
three bands of ~19 kDa, ~24 kDa and ~38 kDa. Furthermore, transgenic tobacco 
plants transformed with the cytosolic construct had no visible or toxic 
phenotypical alternations except kanamycin treatment of the transgenic plants 
resulted in a non-rooting phenotype. Discussion on this aberrant phenotype is 
detailed in the next chapter.  
The truncated 19 kDa protein indicates limited proteolysis resulting in truncation 
of the N-terminal segment of the recombinant protein (Pan et al., 2002).The 19 
kDa protease-resistant core is usually indicative of the aberrant PrP isomer (Ma 
and Lindquist, 2001). However, recombinant mPrP produced in bacteria was 
shown to be susceptible to limited proteolysis resulting in a truncated 19 kDa 
protein (Hornemann et al., 1997). Additionally, studies examining the various 
PrPC isoforms revealed that the truncated 19 kDa protein is also present in the 
brain tissues of healthy mice (Yedidia et al., 2001; Pan et al., 2002). Therefore, 
the presence of this fragment is not indicative of PrPSc molecules. In this study, 
as shown in Appendix A, recombinant mPrP from plants transformed with both 
the cytosolic and ER constructs was completely digested by proteinase K 
treatment indicating that the truncated 19 kDa protein doesn’t represent a true 
PrP species. 
The pathophysiological mechanisms of PrPSc-associated neurodegeneration 
may include changes in the expression, folding, topology, trafficking and 
subcellular localisation of PrPC (Hegde et al., 1998; Walmsley et al., 2001; 
Russelakis-Carnerio et al., 2002; Gasperini et al., 2015). Post-translational 
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modifications of PrPC especially glycosylation regulates the aforementioned 
processes (Heske et al., 2004; Gasperini et al., 2015). Modifications in the 
glycosylation pattern of PrPC during aging has been linked to disease 
development (Gasperini et al., 2015). Also, prion transmission alters the PrPC 
glycoform patterns of infected tissues. For example, prion pathogenesis caused 
by infection with PrPSc strains ME7 and 139A, is associated with increased 
production of aglycosylated PrPC (Russelakis-Carneiro et al., 2002). Although, 
glycosylation is not essential for PrPSc infectivity, it influences the stability of PrPC 
and therefore the incubation time for prion disease (Walmsley and Hooper, 2003; 
Neuendorf et al., 2004). 
Researchers have shown that the glycosylation pattern of PrPC is determined by 
the presence of the GPI anchor and the membrane topology of PrP (Kiachopoulos 
et al., 2005). Therefore, mutations that either disrupt the globular domain of PrPC 
or change the acceptor amino acid in the GPI anchor signal sequence interferes 
with the processing of core glycans and addition of the GPI anchor, possibly 
inducing the generation of PrPSc isomers (Rogers et al., 1993; Chesebro et al., 
2005 Kiachopoulos et al., 2005; Puig et al., 2016). Prion proteins that lack the 
GPI anchor are slowly trafficked through the endoplasmic reticulum and secreted 
as mainly the ~24 kDa aglycosylated or ~31 kDa high mannose glycoform 
(Kiachopoulos et al., 2005; McNally et al., 2009). For example, pathogenic PrP 
mutations PrPT183A and PrPF198S when synthesised lack the GPI anchor, have 
mainly high mannose glycoforms and are partially protease resistant 
(Kiachopoulos et al., 2005).  
Corroboratively, retention of wildtype PrPC in the endoplasmic reticulum using 
ER-targeted anti-prion single chain variable fragments hindered the maturation 
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of the prion protein resulting in increased production of unglycosylated and high 
mannose PrPC isoforms (Cardinale et al., 2005). Furthermore, deletion of the GPI 
anchor signal sequence resulted in production of mainly unglycosylated PrP 
isoforms in scrapie infected mouse neuroblastoma cells (Rogers et al., 1993) and 
transgenic mice (Chesebro et al., 2005). In addition to the endoglycosidase H 
sensitive glycoforms, prion protein retained in the endoplasmic reticulum was 
insoluble in non-ionic detergents and had limited sensitivity to protease digestion 
indicating the protein was misfolded (Rambold et al., 2006; Ashok and Hegde, 
2008). Finally, prevention of complex glycosylation in geldamycin-treated 
neuroblastoma cells increased the formation of high mannose PrP glycoforms 
that were the ideal substrate for conversion of PrPC to PrPSc in scrapie infected 
neuroblastoma cells (Winklhofer et al., 2003). Conversely, Rambold et al. (2006) 
reported that PrPSc molecules in the ER were a poor substrate for prion 
propagation and non-toxic to cells. In addition, Walmsley et al. (2001) reported 
that prolonged retention of PrPC in the endoplasmic reticulum by collapsing the 
Golgi did not induce glycosylation of the protein.  
Recombinant mPrP was targeted to the endoplasmic reticulum of transgenic 
tobacco plants using a C-terminal SEKDEL retention sequence and the N-
terminal signal peptide from PR1a. Western blot analysis revealed three bands 
with molecular weights of ~24 kDa indicating the full length prion protein, a ~31 
kDa isomer possibly indicating the high mannose glycoform and a ~38 kDa 
truncated dimer. The results also indicate that the PR1a signal peptide 
translocated recombinant mPrP to the ER of transgenic tobacco plants although 
there was limited production of the ~31 kDa glycosylated isoform. The results in 
this study is consistent with reports from other studies that expressed GPI-ablated 
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PrP or ER-retained-PrP. Furthermore, a deglycosylation assay to determine if the 
31 kDa band present in plants transformed with the ER construct represents 
glycosylated mPrP was inhibited by aggregation of the isolated recombinant 
protein as shown in Appendix B. 
According to Ashok and Hegde (2008), A4 mutant cells unable to process the 
GPI anchor signal peptide produced PrPC with high mannose glycoforms that 
were rapidly degraded with a half-life of 1-2 hours. This probably explains the low 
level of high mannose PrP glycoform seen in transgenic tobacco plants and 
mammalian cell lines. Walmsley and Hooper (2003) produced anchorless mature 
glycosylated PrPC by modifying the GPI signal peptide of the protein. Therefore, 
mature glycosylated mPrP may be produced in plants using this modified peptide. 
However, given the conformational instability of PrPC, addition of plant specific 
glycans may affect the structure of the prion protein.  This can be rectified by 
using transgenic plants engineered to produce human glycans (Strasser et al., 
2009).  
Misfolded PrP species are usually aggregates and are insoluble in non-ionic 
detergents (Yedidia et al., 2001; Ma and Lindquist, 2001; Kiachopoulos et al., 
2005). Lysis with non-ionic detergent yielded oligomeric mPrP species of various 
molecular weight in plants transformed with both constructs indicating that the 
protein was probably synthesised in a misfolded isoform and aggregated (Section 
6.2.2.2 – 6.2.2.5). Therefore, this study has shown that transgenic tobacco plants 
can successfully synthesise two mutant mPrP species in a similar manner to 
mammalian transgenic lines. However, expression levels of the protein were low 
with the highest expression level for plants transformed with the cytosolic 
construct at 0.0024% TSP and for plants transformed with the ER construct at 
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0.0016% TSP. A possible reason for the low expression levels of recombinant 
mPrP is its very short half-life. Wild-type PrPC has a half-life of ∼2.6 hours while 
N-terminally truncated PrPC has a half-life of ∼4.8 hours (Nunziante et al., 2003). 
This study has characterised recombinant mPrP targeted to different cellular 
compartments in transgenic tobacco leaves. As described earlier, comparable 
features of neurodegenerative diseases implies that understanding the 
pathological mechanism of any neurodegenerative disease may significantly 
impact diagnostics and therapy for other neurodegenerative diseases. Therefore, 
the infectious nature of the prion protein makes it uniquely primed for designing 
studies to explain the pathogenic mechanisms underlying neurodegenerative 
diseases (Ross and Poirier, 2004; Chiti and Dobson, 2006; Prusiner, 2012).  
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5 Phenotypic analysis of transgenic tobacco 
leaves expressing recombinant mPrP 
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5.1 Introduction  
The prion protein binds several divalent metal ions mainly within its octapeptide 
repeat region. Therefore, several speculative functions were assigned to PrPC in 
relation to metal homeostasis particularly copper transport and protection of cells 
against oxidative damage (Jackson et al., 2001; Rana et al., 2009; Singh et al., 
2010).  Experimental evidence suggests that prion metal interactions have 
structural and functional consequences. For instance, PrPC expressed in 
neuronal cells are endocytosed rapidly in the presence of physiological relevant 
concentrations of copper and zinc (Perera and Hooper, 2001). Furthermore, 
spectroscopic studies have shown that the unstructured N-terminal region of the 
prion protein undergoes a conformational change when bound to copper ions. 
Finally, PrPC expression levels are affected by metal ions. For example, reducing 
dietary copper levels or increasing dietary manganese levels has a 
corresponding effect on PrPC expression levels (Kralovicova et al., 2009).  
Metals are associated with the physiopathology of prion disease and prion 
pathogenesis is dependent on its association with Cu2+, Zn2+ and Mn2+ ions 
(Wong et al., 2001; Lehmann, 2002). Researchers hypothesised that PrPSc 
results from metal altered conformation of PrPC, hence PrPSc associated 
neurotoxicity is a deleterious consequence of metal dyshomeostasis (Lehmann, 
2002; Rana et al., 2009). Corroboratively, toxic levels of cuprizone a copper 
chelator induced histopathological changes similar to scrapie in mice (Pattison 
and Jebbet, 1971). Furthermore, metal induced free radicals expedite 
neurotoxicity in other neurodegenerative diseases including Alzheimer’s, 
Huntington’s and Parkinson’s diseases (Lehmann, 2002; Singh et al., 2010). 
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Various researchers have established a relationship between prion disease and 
metal ions. For example, Thackray et al. (2002) showed that manganese levels 
increased and copper levels decreased in the brain prior to clinical onset of prion 
disease. Additionally, manganese replaces copper competitively when bound to 
PrPC (Brown et al. 2000) and alters recombinant PrPC to PrPSc in a time 
dependant manner (Brown et al. 2000; Hesketh et al., 2012). 
Prion strain specific phenotype can be determined by the glycosylation pattern 
and conformation of a PrPSc specie (Collinge, 2001; Jackson, 2001). Since metal 
ion occupancy influences the conformation of PrPSc strains, therefore, PrPSc 
interaction with metal ions possibly explains the diversity of prion strains in human 
and animals (Wadsworth et al., 1999). For example, two different strains of 
classical human CJD can be interconverted in vitro by altering their metal ion 
occupancy (Wadsworth et al., 1999). Also, Brim et al. (2016) showed using high 
speed centrifugation that PrPC–Zn2+ interaction reduces the solubility of full length 
glycosylated PrPC while aminoterminally truncated full length PrPC and 
unglycosylated PrPC remained in solution. This study examines the possible 
phenotypic effects of expressing recombinant mPrP in transgenic tobacco plants. 
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5.2 Results  
5.2.1 Kanamycin induced phenotypic changes in transgenic tobacco 
plants transformed with the pGreen-35S-mPrP-Cyto construct 
To select tobacco transformants, regenerated shoots were excised from tobacco 
calli and transferred to MS media supplemented with kanamycin (100 µg/ml). 
Phenotypic alternations were observed in transgenic plants transformed with the 
pGreen-35S-mPrP-Cyto construct (Figure 5.1). All pGreen-35S-mPrP-Cyto 
transformants exhibited no root development while plants transformed with either 
the pGreen35SmPrP-ER construct or the control pGreen vector (Figure 5.2) 
developed roots when transplanted to MS media supplemented with kanamycin. 
However, transgenic plants transformed with the pGreen-35S-mPrP-Cyto 
construct developed roots when transplanted to MS media only (Figure 5.2). 
 
 
 
 
 
 
 
 
 
A      B  
Figure 5.1: 15-day-old transgenic plant transformed with the pGreen-35S-mPrP-
Cyto construct grown either in MS media supplemented with kanamycin (A) or 
MS media only (B).  
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5.2.2 Chemical analysis of transgenic tobacco plant leaves 
To screen for possible phenotypic effects of expressing recombinant mPrP in 
transgenic tobacco plants, leaves from 30-day-old transgenic tobacco lines 
transformed with either the pGreen-35S-mPrP-Cyto construct (Lines C4, C9 and 
C12), pGreen-35S-mPrP-ER construct (Lines E1, E4 and E7) and control plants 
transformed with the pGreen vector (Lines P1, P2 and P3) were chemically 
analysed to determine the concentration of several macroelements and 
Figure 5.2: 30-day-old transgenic plants grown either in MS media 
supplemented with kanamycin: pGreen-35S-mPrP-Cyto construct (A) and 
pGreen construct (C) or MS media only: pGreen-35S-mPrP-Cyto construct (B) 
and pGreen construct (D) 
A    B  
C    D  
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microelements. The transgenic plants expressing recombinant mPrP were 
chosen based on similar RNA expression levels. Furthermore, the plants were 
either micropropagated in MS media only or MS media supplemented with 
kanamycin (100 µg/ml) to evaluate possible effects of the non-rooting phenotype 
exhibited by pGreen-35S-mPrP-Cyto constructs when exposed to kanamycin.  
5.2.2.1 Analysis of macroelements 
The macroelements nitrogen (N; Figure 5.3), phosphorus (P; Figure 5.4), 
potassium (K; Figure 5.5), calcium (C; Figure 5.6), and magnesium (Mg; Figure 
5.7) were analysed. 
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Figure 5.3: Comparison of nitrogen content of transgenic tobacco leaves from 
the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data represents mean and standard error of mean of three independent 
plants from each construct. Two-way ANOVA with Bonferroni post hoc analysis 
indicates that subcellular localization of the recombinant mPrP factor and kanamycin 
factor each has a statistically significant effect on nitrogen concentration. Also, the 
interaction between both factors has a statistically significant effect on nitrogen 
concentration. Significant differences are depicted as *P<0.05, **P<0.001, and 
***P<0.0001. 
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Figure 5.4: Comparison of phosphorus content of transgenic tobacco leaves 
from the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER 
constructs grown either in MS media or MS media supplemented with 
kanamycin (100 µg/ml). Data represents mean and standard error of mean of three 
independent plants from each construct. Two-way ANOVA analysis with Bonferroni 
post hoc analysis indicates that only the subcellular localization of the recombinant 
mPrP has a statistically significant effect on phosphorus concentration. Significant 
differences are depicted as *P<0.05. 
Figure 5.5: Comparison of potassium content of transgenic tobacco leaves 
from the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER 
constructs grown either in MS media or MS media supplemented with 
kanamycin (100 µg/ml). Data represents mean and standard error of mean of three 
independent plants from each construct. Two-way ANOVA analysis with Bonferroni 
post hoc analysis indicates the interaction between subcellular localization of the 
mPrP factor and kanamycin factor has a statistically significant effect on potassium 
concentration. Also, subcellular localization of the mPrP factor has a significant effect 
on potassium concentration. Significant differences are depicted as *P<0.05. 
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Figure 5.6: Comparison of calcium content of transgenic tobacco leaves from 
the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data represents mean and standard error of mean of three independent 
plants from each construct. Two-way ANOVA analysis indicates no statistically 
significant effect on calcium concentration.  
 
 
 
 
 
Figure 5.7: Comparison of magnesium content of transgenic tobacco leaves 
from the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER 
constructs grown either in MS media or MS media supplemented with 
kanamycin (100 µg/ml). Data represents mean and standard error of mean of three 
independent plants from each construct. Two-way ANOVA analysis indicates no 
statistically significant effect on magnesium concentration.  
.,   
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The results indicates that nitrogen concentration was affected by the subcellular 
localisation of the recombinant mPrP (P<0.0001), kanamycin treatment 
(P=0.0093) and the interaction of subcellular localisation and kanamycin 
treatment (P=0.00358). Bonferroni post hoc analysis revealed that kanamycin-
treated transgenic tobacco plants transformed with the pGreen-35S-mPrP-Cyto 
construct had reduced nitrogen concentration compared to untreated plants 
transformed with either the pGreen-35S-mPrP-Cyto construct (P=0.0296), 
pGreen-35S-mPrP-ER construct (P=0.0001) or pGreen vector (0.0073) and 
kanamycin-treated transgenic plants transformed with either the pGreen vector 
(p=0.0045) or pGreen-35S-mPrP-ER construct (P=0.0013).  
Phosphorus concentration was significantly affected solely by the subcellular 
localisation of the recombinant protein (P=0.0008).  Transgenic leaves from 
kanamycin-treated plants transformed with the pGreen-35S-mPrP-Cyto construct 
had significantly reduced phosphorus concentration compared to kanamycin-
treated plants transformed with either the pGreen vector (P=0.0207) or pGreen-
35S-mPrP-ER construct (P=0.0127) and untreated plants transformed with the 
pGreen-35S-mPrP-ER construct (P=0.0398) as observed by Bonferroni post hoc 
analysis.  
Potassium concentration was significantly influenced by subcellular localisation 
of the recombinant mPrP (0.0316) and the interaction between kanamycin 
treatment and subcellular localisation (P=0.0087). Bonferroni post hoc analysis 
showed that kanamycin-treated plants transformed with the pGreen-35S-mPrP-
Cyto construct had significantly reduced potassium content compared to 
kanamycin-treated plants transformed with the pGreen vector (P=0.0142) or 
pGreen-35S-mPrP-ER construct (P=0.0405) and untreated plants transformed 
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with either the pGreen-35S-mPrP-Cyto construct (P=0.0200) or the pGreen-35S-
mPrP-ER construct (P=0.0132). Kanamycin treatment, subcellular localisation 
and the interaction between subcellular localisation and kanamycin treatment had 
no significant effect on magnesium and calcium concentrations.  
5.2.2.2 Analysis of microelements 
The microelements iron (Fe; Figure 5.8), manganese (Mn; Figure 5.9), copper 
(Cu; Figure 5.10), boron (B; Figure 5.11), nickel (Ni; Figure 5.12) and zinc (Zn; 
Figure 5.13) were analysed. 
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Figure 5.8: Comparison of iron content of transgenic tobacco leaves from the 
pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data and mean of three independent plants from each construct are depicted. 
Two-way ANOVA with Bonferroni post hoc analysis indicates the interaction between 
subcellular localization of the recombinant mPrP and kanamycin has a statistically 
significant effect on iron concentration. Significant differences are depicted as 
*P<0.05.  
.,   
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Figure 5.10: Comparison of copper content of transgenic tobacco leaves from 
the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data and mean of three independent plants from each construct are depicted. 
Two-way ANOVA analysis indicates no statistically significant effect on copper 
concentration. 
.,   
Figure 5.9: Comparison of manganese content of transgenic tobacco leaves 
from the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER 
constructs grown either in MS media or MS media supplemented with 
kanamycin (100 µg/ml). Data and mean of three independent plants from each 
construct are depicted. Two-way ANOVA analysis indicates no statistically significant 
effect on manganese concentration. 
.,   
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Figure 5.11: Comparison of boron content of transgenic tobacco leaves from 
the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data and mean of three independent plants from each construct are depicted. 
Two-way ANOVA analysis indicates no statistically significant effect on boron 
concentration. 
.,   
Figure 5.12: Comparison of nickel content of transgenic tobacco leaves from 
the pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data and mean of three independent plants from each construct are depicted. 
Two-way ANOVA analysis indicates no statistical significant effect on nickel 
concentration. 
.,   
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From the results, iron concentration was significantly influenced solely by the 
interaction of subcellular localisation of the recombinant mPrP and kanamycin 
treatment (P=0.0089). Bonferroni post hoc analysis showed that untreated leaves 
from plants transformed with the pGreen-35S-mPrP-Cyto construct had 
significantly higher concentration of iron than kanamycin-treated plants 
transformed with either the pGreen vector (P=0.0391) or the pGreen-35S-mPrP-
Cyto construct (P=0.0232) and untreated plants transformed with the pGreen 
construct (P=0.0264).  
Zinc concentration was significantly affected solely by kanamycin treatment 
(P=0.0391). However, Bonferroni post hoc analysis revealed no significant 
pairwise comparisons. Subcellular localisation of the recombinant mPrP, 
kanamycin treatment and their interaction had no significant effect on 
manganese, copper, boron and nickel concentrations. However, average 
Figure 5.13: Comparison of zinc content of transgenic tobacco leaves from the 
pGreen, pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs 
grown either in MS media or MS media supplemented with kanamycin (100 
µg/ml). Data and mean of three independent plants from each construct are depicted. 
Two-way ANOVA analysis indicates that only kanamycin has a statistically significant 
effect on zinc concentration. 
.,   
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manganese concentration was increased in untreated transgenic lines 
transformed with cytosolic-mPrP compared to kanamycin-treated plants. 
Although, this result is not statistically significant because of the spread in the 
untreated data set. Similarly, the mean copper concentration was increased ~3-
fold in transgenic lines transformed with the ER-mPrP construct compared to 
other tested transgenic lines and kanamycin-treated plants transformed with the 
pGreen-35S-mPrP-ER construct.  However, this result is not significant due to 
the spread of the data.  
5.2.3 Effect of recombinant prion expression and kanamycin treatment 
on peroxidase activity in transgenic tobacco leaves  
Transgenic tobacco leaves were analysed to determine if recombinant mPrP 
expression had any effect on peroxidase activity of transgenic tobacco leaves. 
The transgenic lines analysed were identical to those used for chemical analysis. 
However, two way ANOVA analysis indicates that neither the subcellular 
localisation, kanamycin treatment nor their interaction had a statistically 
significant influence on peroxidase activity in the transgenic lines analysed. 
Seemingly, recombinant mPrP may have a modulatory effect on peroxidase 
activity in transgenic tobacco plants. As shown in Figure 5.14, compared to the 
control plants, there was less interplant variability of peroxidase activity in plants 
transformed with both the pGreen-35S-mPrP-Cyto construct and the pGreen-
35S-mPrP-ER construct grown on MS media only. 
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Figure 5.14: Peroxidase assay of transgenic tobacco leaves from the pGreen, 
pGreen-35S2-mPrP-Cyto and pGreen-35S2-mPrP-ER constructs grown either 
in MS media or MS media supplemented with kanamycin (100 µg/ml). Data and 
mean of three independent plants from each construct are depicted. Two-way 
ANOVA analysis indicates no statistically significant effect on peroxidase activity. 
.,   
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5.3 Discussion 
Putative transgenic tobacco shoots were screened based on their resistance to 
kanamycin, an aminoglycoside antibiotic which has a negative effect on non-
transformed shoots. Several studies have shown that in plants, aminoglycoside 
antibiotics binds to mitochondria and chloroplast ribosomes to subdue translation 
termination, cause misreading of the mRNA, interact with the plasma membrane 
and its receptors and at high concentrations inhibit protein synthesis (Padilla and 
Burgos, 2010). The transgene constructs used in this study included the 
selectable marker gene NptI which codes for neomycin phosphotransferase, a 
bacterial enzyme that inhibits the activity of aminoglycoside antibiotics (Yenofsky 
et al., 1990). Transgenic plants transformed with the pGreen vector and the 
pGreen-35S-mPrP-ER construct developed roots when treated with kanamycin 
(100ug/ml). Unexpectedly, root morphogenesis was inhibited when transgenic 
tobacco plants transformed with the pGreen-35S-mPrP-Cyto construct were 
exposed to kanamycin treatment. Although, this effect was reversible when the 
transgenic plants were micropropagated on untreated MS media. Detailed 
analysis is required to determine the effect of kanamycin treatment on root 
morphogenesis in transgenic plants transformed with the cytosolic-mPrP 
construct. 
The non-rooting phenotype occurred, possibly because transgenic tobacco 
plants expressing recombinant mPrP in the cytosol were all periclinal chimeras. 
Chimeric shoots may have reduced nptI activity, thereby not providing essential 
resistance levels to prevent kanamycin treatment from inhibiting root 
morphogenesis (Faize et al., 2010; Schmulling and Schell, 1993). However, since 
identical pGreen vectors and procedures were used to transform all the 
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constructs this scenario seems highly implausible given the 100% prevalence of 
this effect amongst independent transgenic plants transformed with the pGreen-
mPrP-35S-Cyto construct. Alternatively, recombinant mPrP may enhance the 
effect of kanamycin on plant cells. According to Padilla and Burgos (2010) growth 
media constituents affects kanamycin activity. For instance, chelators such as 
EDTA enhance the effect of kanamycin while Ca2+ alleviates the toxic effect of 
kanamycin. Nevertheless, the non-rooting phenomenon did not occur in plants 
transformed with the ER construct rendering this hypothesis improbable except 
the interaction of kanamycin is dependent on the subcellular localisation of the 
recombinant mPrP. 
The most plausible explanation is that changes in essential nutrients profile of 
transgenic plants transformed with the cytosolic construct affected root initiation 
in the presence of kanamycin. For instance, primary root elongation is inhibited 
in Arabidopsis thaliana when grown on phosphate deficient soils in the presence 
of optimal iron levels, however, reduced iron concentration without increased 
phosphate concentration altered this phenotype (Ward et al., 2008). Additionally, 
Niu et al. (2015) showed that root elongation directly correlates with the level of 
phosphorus in the growth medium and this effect was modulated by the level of 
magnesium in the medium. At high magnesium concentration, the effect of 
phosphorus on root elongation is enhanced while at low magnesium 
concentration the effect is reduced.  In this study, nutrient analysis of various 
transgenic plants revealed that transgenic plants transformed with the cytosolic-
mPrP construct had reduced phosphorus concentration compared to the other 
transgenic lines tested (Figure 5.4). Furthermore, phosphorus concentration is 
significantly reduced in kanamycin-treated transgenic plants expressing 
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cytosolic-mPrP compared to other kanamycin-treated transgenic lines. A possible 
explanation for upregulation of phosphorus in plants transformed with the pGreen 
vector and ER-mPrP construct after kanamycin treatment is that NptI inactivates 
kanamycin by phosphorylation. This implies that in the presence of kanamycin, 
phosphorus uptake is increased in transgenic plants, however, phosphorus 
concentration is reduced in plants transformed with the cytosolic-mPrP construct. 
Therefore, the non-rooting phenotype may be explained by the reduced 
availability of phosphorus in kanamycin-treated transgenic tobacco plants 
transformed with the cytosolic construct. If this theory is proven it indicates that 
phosphorylation assays may indicate accumulation of cytosolic PrP in cells. 
Although, this is dependent on analogous nutrient profiles in plant and 
mammalian cells overexpressing cytosolic-mPrP.  
Mutation in tobacco rac gene causes a non-rooting phenotype in tobacco plants 
characterised by increased concentrations of auxin and the polyphenolic 
compounds chlorogenic acid and rutin (Lund et al., 1997; Faivre-Rampant et al., 
2002). Kevers et al. (2001) showed that exogenous application of increasing 
concentrations of indole-3-butyric acid (IBA) and 1-napthalene acetic acid (NAA) 
elicits a response in wild type shoot, increasing root proliferation at optimal 
concentration followed by inhibition at above optimal concentration whereas both 
homozygous and heterozygous rac mutants were nonresponsive. Furthermore, 
stem tips treated with chlorogenic acid accumulated auxin and did not develop 
adventitious roots compared to control plants (Faivre-Rampant et al., 2002). In 
this study, attempts to induce rooting by supplementing growth media with NAA 
(5mg/L) did not reverse the kanamycin induced phenotype.  
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Plant neurobiologists dedicated to understanding signalling in plants have 
recognised analogies between the central nervous system and root cells at the 
apical meristem (Baluska et al., 2006). For instance, the protein alastin is 
homologous to the RHD3 protein of Arabidopsis. Mutation in alastin causes 
hereditary spastic paraplegia a neurodegenerative disorder that affects the axons 
of the longest neurons and results in impaired control of leg muscles. Conversely, 
RHD3 protein is vital in Arabidopsis for the growth and development of root hairs 
(Baluska, 2010). Auxins are plant hormones with morphogen-like characteristics, 
essential for root development (Benkova et al., 2009). The mechanisms of auxin 
transport is comparable to neurotransmitter release from neuronal cells. Also, 
auxins cooperate with cell wall peroxidases to induce the formation of reactive 
oxygen species which are important for plant signalling (Brenner et al., 2006). 
Coincidentally, chlorogenic acid and rutin have been studied as therapeutic 
agents for neurodegenerative disorders. Chlorogenic acid may help alleviate 
neurodegenerative diseases such as ischemic stroke caused by glutamate 
neurotoxicity (Mikami and Yamazawa, 2015) while rutin due to its ability to chelate 
iron protects neurons from neurotoxicity of 6-hydroxydopamine (6-OHDA) which 
induces Parkinson’s disease in rats (Khan et al., 2012). Hypothetically, 
understanding the mechanism behind the inhibition of root development in 
kanamycin-treated transgenic plants expressing recombinant mPrP in the cytosol 
may offer insight into understanding the prion phenomenon. 
In plants, shoots and roots are strongly interdependent on one another such that 
any factor that inhibits the development of one affects the other. Roots provides 
anchorage, synthesise hormones important for shoot development and absorbs 
water and inorganic nutrients from the soil or growth medium (Hodge et al., 2009). 
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Expression of recombinant mPrP and kanamycin treatment modified nutrient 
uptake in plants and inhibited root morphogenesis in transgenic tobacco plants.  
Analysis of macronutrients showed that transgenic plants expressing 
recombinant mPrP in the cytosol had significantly reduced uptake of nitrogen, 
phosphorus and potassium. The non-rooting phenotype significantly affected 
nitrogen and phosphorus uptake. Furthermore, the subcellular localisation of the 
recombinant protein affected potassium, phosphorus and nitrogen concentration 
while kanamycin treatment significantly affected nitrogen concentration. 
Micronutrient analysis revealed that the interaction between kanamycin and 
cytosolic recombinant mPrP, conceivably responsible for the non-rooting 
phenotype significantly affected iron uptake. Compared to control plants and 
kanamycin-treated transgenic plants expressing cytosolic recombinant mPrP, 
iron concentration was significantly increased in untreated transgenic plants 
expressing recombinant mPrP in the cytosol while kanamycin significantly 
reduced the uptake of zinc in mPrP transgene constructs and the control plant. 
Kanamycin may act as a zinc chelator in MS media thus affecting its uptake by 
plants. Interestingly, the statistically significant differences observed in nutrient 
analysis is independent of recombinant mPrP concentrations in the transgenic 
plant lines analysed. 
A literature search has revealed no direct association between the 
macronutrients, significantly affected by mPrP expression and/or kanamycin 
treatment of transgenic plants, and PrPC or PrPSc. However, studies have 
revealed that PrPC interacts with proteins involved in potassium ion transport. For 
instance, PrPC binds potassium channel tetramerization domain containing 
protein (KCTD1) within its unstructured N-terminal region (Huang et al., 2012) 
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and interacts with dipeptidyl aminopeptidase-like protein 6 (DPP6) to modulate 
A-type potassium currents (Mercer et al., 2013). Also, phosphorus containing 
dendrimers interacts with PrPC and prevents PrPSc accumulation in 
neuroblastoma cells. Alternatively, the observed effects on macroelements may 
be indirectly influenced by the effect of mPrP on microelements. Malakouti (2008) 
has shown that microelements especially iron influences the activity of 
macroelements. 
PrPC has been reported to act as a ferriredutase while pathogenesis of its 
aberrant isoform PrPSc is associated with iron dyshomeostasis (Singh et al., 
2010). According to Singh et al. (2009), aberrant prion protein sequesters ferritin 
into detergent insoluble PrPSc-ferritin complexes in PrPSc infected cells resulting 
in an iron deficiency phenotype. Subsequently, the phenotype induces 
upregulation of cellular iron content by upregulating transferrin and transferrin 
receptor and downregulating ferritin. However, iron is highly reactive and involved 
in the oxidative stress inducing Fenton and Haber-Weiss reactions. Therefore, 
iron dyshomeostasis probably induces neurotoxicity in prion disease (Singh et 
al., 2014). Also, PrPSc-ferritin complex is associated with the transport of PrPSc 
across intestinal epithelial cells, probably enabling PrPSc infection across species 
barrier (Mishra et al., 2004; Sunkesula et al., 2010). Remarkably, ferritin is 
structurally conserved in plants and animals and studies in plant have associated 
ferritin with protection against the effects of oxidative stress (Briat et al., 2010). 
Compared to control plants manganese concentration increased in two 
transgenic lines expressing recombinant mPrP in the cytosol while copper 
concentration increased in two transgenic lines expressing recombinant mPrP in 
the endoplasmic reticulum. The variability in the result may be explained by 
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differences in protein concentration since samples were analysed from 
heterogeneous transgenic lines. This indicates that a threshold concentration 
may be required for PrP-metal interactions.  The results also indicate that 
subcellular localisation affects the prion protein affinity for metal ions. Therefore, 
prion strains and characteristics are probably influenced by subcellular 
localisation of the aberrant prion protein. For instance, GSS and vCJD are 
associated with iron and ferritin deposits while iron deposits are absent in sCJD 
suggesting distinct pathogenesis pathways (Petersen et al., 2005). 
Unexpectedly, the results show that kanamycin’s interaction with the recombinant 
mPrP affects its ability to chelate Cu2+ ion, Mn2+ ions and regulate peroxidase 
activity in transgenic tobacco plants transformed with both mPrP constructs. 
Consequently, kanamycin should be investigated as a therapeutic agent against 
prion disease. However, kanamycin effectiveness as a therapeutic agent may be 
hindered by its inability to penetrate the blood brain barrier in adults (Nau et al., 
2010) and as stated earlier the possible harmful phenotype exhibited in 
kanamycin-treated transgenic plants expressing cytosolic recombinant mPrP.  
A proposed function of the cellular prion protein is protection against oxidative 
stress via its influence of copper metabolism and superoxide dismutase (SOD) 
activity. This putative function is supported by in vitro recombinant prion protein 
superoxide dismutase-like activity, increased susceptibility to copper toxicity, 
oxidative stress and decreased Cu/Zn-SOD activity in PRNP ablated mice (Brown 
and Besinger, 1998; Brown et al., 1999; Milhavet et al., 2000). Contrarily, other 
in vivo studies suggest that PrPC had no impact on SOD activity and no SOD-like 
activity (Hutter et al., 2003). This study analysed the effect of expressing 
recombinant mPrP expression in the endoplasmic reticulum and cytosol on 
109 
 
peroxidase activity in transgenic tobacco leaves. Interestingly, the results showed 
that transgenic leaves treated with kanamycin and untreated control displayed 
variation in peroxidase activity while untreated plants expressing recombinant 
mPrP had less variable peroxidase activity. This suggests that the recombinant 
mPrP may have a modulatory effect on peroxidase activity in transgenic tobacco 
leaves. Brown and Besinger (1998) discovered that Tg35 cerebellar cells 
overexpressing PrPC had increased glutathione peroxidase (GPX) expression 
and sensitivity to hydrogen peroxide compared to wildtype and PRNP ablated 
cells. Therefore, they hypothesised that increased superoxide dismutase activity 
increased the levels of hydrogen peroxide which induces oxidative stress. 
Alternatively, peroxidase contains haem and is probably affected by iron 
sequestration. Additionally, Rout et al. (2013) showed that copper toxicity 
reduced the activities of the antioxidant enzymes superoxide dismutase, 
glutathione peroxidase and catalase in Withania somnifera L. seedlings. 
Therefore, it is probable that overexpression of recombinant mPrP in transgenic 
tobacco leaves and its effect on metal homeostasis impaired peroxidase activity.  
The aberrant isoform of the prion protein is neurotoxic and associated with 
increased susceptibility to oxidative stress. Reduced superoxide dismutase and 
glutathione peroxidase activity has been associated with impaired resistance to 
reactive oxygen species in prion infected and PRNP ablated cells and onset of 
clinical symptoms of prion disease in mice (White et al., 1999; Wong et al., 2001; 
Gudmundsdóttir et al., 2008). For instance, hypothalamic neuronal GT1 cells 
infected with prions had drastically reduced glutathione and superoxide 
dismutase antioxidant activity compared to uninfected control cells (Milhavet et 
al., 2000). Furthermore, analysis of glutathione peroxidase activity in ewes from 
110 
 
farms in scrapie infected and scrapie free area revealed that ewes from scrapie 
infected farms had significantly lower glutathione peroxidase activity 
(Gudmundsdóttir et al., 2008). Therefore, it is conceivable that the transgenic 
tobacco leaves produces structurally aberrant recombinant mPrP in both the 
cytosol and endoplasmic reticulum.  
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6 Purification strategy for recombinant mPrP 
expressed in tobacco plants  
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6.1 Introduction  
Prion research over several decades has generated significant information to 
support the infectious misfolded protein theory. Firstly, the genetic sequence of 
normal cellular prion protein has been isolated and cloned successfully (Lee et 
al., 1998). Secondly, PRNP knockout mice are resistant to prion infectivity (Bueler 
et al., 1992). Thirdly, the prion phenomenon occurs in yeast and other fungi, 
useful systems for studying the role of chaperones in prion infectivity (Wickner, 
2007). Fourthly, novel infectious prion aggregates have been generated in vitro 
using recombinant prion protein produced in bacteria (Castilla et al., 2005). 
Finally, development of protein misfolding cyclic amplification (PMCA) has the 
potential to improve prion disease diagnosis significantly (Saborio et al., 2001). 
However, despite the advances in prion research, the biophysical and 
biochemical aspects of prion disease are still an enigma (Cobb and Surewicz, 
2009). Therefore, research to elucidate the mechanism of prion propagation will 
require purified recombinant prion protein in substantial quantities for detailed 
studies of prion pathogenicity and the role of glycosylation in its conversion.  
This study evaluates the possibility of purifying recombinant mouse prion protein 
from tobacco plants using IMAC technology. Recombinant mouse prion protein 
has been expressed in transgenic tobacco plants. To facilitate its purification, a 
C-terminal hexahistidine-tag was fused to the synthetic mouse prion gene. 
Histidine-tagged proteins are purified using immobilised metal affinity 
chromatography (IMAC) (Hochuli et al., 1988). IMAC purification of affinity tagged 
proteins (Porath et al., 1975) is cheap and usually only requires a single step 
process. Affinity purification of recombinant protein since its inception has been 
widely used to purify recombinant proteins from various heterologous expression 
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systems. Furthermore, greater than 60% of structurally studied proteins were 
purified via a polyhistidine-tag (Arnau et al., 2006). Histidine affinity tails have 
been successfully used to purify recombinant proteins from tobacco plants 
(Leelavathi and Reddy, 2003; Lige et al., 1998; Valdez-Ortiz, 2005). Bacterially 
expressed recombinant mouse prion protein has been purified using histidine 
affinity tails (Makarava and Baskakov, 2012).  
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6.2 Results  
6.2.1 Purification Strategy 
The purification strategy for recombinant mPrP is summarised in Figure 6.1. 
Transgenic tobacco leaves expressing recombinant mPrP were homogenised 
and dispersed in a variety of buffers (Table 2.2). the physicochemical properties 
of the two detergents used, Triton X-100 and CHAPS are reported in Table 2.3. 
The resulting lysate was centrifuged and the supernatant was either pretreated 
with ammonium sulphate fractionation prior to the IMAC step or passed directly 
through an IMAC column. Subsequently, various IMAC fractions were analysed 
for protein purity by SDS-PAGE or western blot.  
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Figure 6.1: Flowchart of steps involved in recombinant mPrP extraction from 
transgenic tobacco plants  
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6.2.2 Extraction of recombinant mPrP  
Membrane-associated recombinant mPrP was present in transgenic tobacco 
plants expressing both the cytosolic and the endoplasmic reticulum (ER) gene 
constructs. In an attempt to purify the recombinant protein using IMAC 
chromatography the leaves were lysed under various buffer conditions given in 
Table 2.2 and described below. 
6.2.2.1 Transgenic leaves lysed with buffer A 
Aglycosylated mPrP was expressed in the cytosol of transgenic tobacco leaves 
transformed with cytosolic-mPrP constructs. Homogenised transgenic leaves 
was mixed with buffer A at a 1:5 ratio (tissue: buffer). The mixture frozen in liquid 
nitrogen and thawed in a bath sonicator (Clifton MU-8) for 5 minutes. This process 
was repeated 10 times to lyse the cells prior to centrifugation.  The clarified lysate 
subjected to IMAC purification using a HiTrap Chelating HP column (GE 
Healthcare) charged with nickel (Ni2+) ions.   From the result (Figure 6.2), a 24 
kDa protein indicating the recombinant aglycosylated prion protein was 
successfully purified from the cytosolic fraction of transgenic leaves in a one-step 
IMAC process. 
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Figure 6.2: Purification of His-tagged cytosolic recombinant mPrP from 
transgenic tobacco leaves extract. Tobacco leaves were lysed with Buffer A and 
IMAC fractionated. Fractions were collected during the purification process and 
analysed by A) SDS-PAGE followed by coomassie blue staining and B)Western Blot, 
probed using HRP conjugated 6X-His-tag antibody (1:2,500 dilution ). Lane 1: Protein 
standard. Lane 2: Lysate. Lane 3: Flow through. Lanes 4 – 6: Washes. Lanes 7 – 8: 
Eluates. Lane 10: Control – recombinant mPrP from E. coli. 
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6.2.2.2 Transgenic leaves lysed with buffer B 
In order to extract the recombinant mPrP in its native form, transgenic plant 
leaves expressing both gene constructs and wild type tobacco plants  were lysed 
with buffer B at a 1:10 ratio (tissue: buffer) and passed through a HiTrap Chelating 
HP column (GE Healthcare) charged with nickel (Ni2+) ions.  The eluate fractions 
were pooled, buffer exchanged to deionised water and concentrated using Pierce 
protein concentrators, 10K MWCO (Thermo Fisher Scientific). Fractions from 
plants expressing the transgenic constructs and the control plant were analysed 
by SDS-PAGE electrophoresis and western blot (Figure 6.3). From SDS-PAGE 
analysis, the recombinant protein was not purified to homogeneity (Figure 6.3 a). 
Western blot analysis (Figure 6.3 b) was negative for the wild type plant extract, 
eluate from transgenic plants expressing the ER constructs displayed a faint 
positive band of 24 kDa, similar to the control protein while the cytosolic construct 
eluate while eluate from the cytosolic construct indicated a strong positive band 
of approximately 60 kDa. 
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Figure 6.3: Purification of His-tagged recombinant mPrP from transgenic 
tobacco leaves extract. Tobacco leaves expressing both the cytosolic and ER 
constructs were lysed with Buffer B and IMAC fractionated. Fractions were collected 
during the purification process and analysed by A) SDS-PAGE followed by 
coomassie blue staining and B) Western Blot, probed using HRP conjugated 6X-His-
tag antibody (1:2,500 dilution). Lane 1: Protein standard. Lane 2: Wild type eluate. 
Lane 3: Eluate from transgenic lines expressing mPrP in the ER. Lane 4: Eluate from 
transgenic lines expressing mPrP in the cytosol. Lane 5: Control – recombinant mPrP 
from E. coli. 
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6.2.2.3 Transgenic leaves lysed with buffer C 
To investigate the lack of recombinant mPrP in the eluate lysed with buffer B, 
transgenic tobacco plants expressing cytosolic-mPrP were lysed with a 
denaturing buffer (Buffer C) at a 1:2 ratio (tissue: buffer). The clarified lysate was 
fractionated using HiTrap Chelating HP column (GE Healthcare) charged with 
nickel (Ni2+) ions. The resultant fractions were analysed by western blot (Figure 
6.4). The result suggests the recombinant mPrP misfolded as soluble aggregates 
present in the clarified lysate. Also, the recombinant protein was found in the flow 
through fraction, indicating that the prion aggregates had no affinity for nickel 
ions. 
 
 
Figure 6.4: Purification of His-tagged cytosolic recombinant mPrP from 
transgenic tobacco leaves extract. Tobacco leaves were lysed with Buffer C and 
IMAC fractionated. Fractions were collected during the purification process and 
analysed by Western Blot, probed using HRP conjugated 6X-His-tag antibody 
(1:2,500 dilution). Lane 1: Lysate. Lane 2: Flow through. Lanes 3 – 5: Washes. Lanes 
6 – 7: Eluates. Lane 8: Control 1 – crude extract from transgenic tobacco leaves 
expressing recombinant mPrP in the ER. Lane 9: Control 2 – recombinant mPrP from 
E. coli. 
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6.2.2.4 Ammonium Sulphate fractionation of extracts 
To examine if soluble plant contaminants such as alkaloids affected recombinant 
mPrP solubility, transgenic tobacco leaves expressing the ER-mPrP construct 
were lysed with non-denaturing buffer C at a 1:5 ratio (tissue: buffer). The clarified 
lysate was fractionated using ammonium sulphate as described by Scopes 
(2013), the precipitate from various fractions were resuspended in buffer C and 
desalted prior to western blot analysis. Also, to determine if recombinant mPrP 
was completely solubilised, pellets obtained from crude lysate centrifugation were 
solubilised in Laemmli buffer at a 1:2 ratio, sonicated and incubated at 90°C for 
10 minutes. Then, the clarified lysate analysed by western blot. From the result 
(Figure 6.5), recombinant mPrP was precipitated as a dimer in the 40% 
ammonium sulphate saturated fraction and as oligomers in both the 50% and 
60% fractions. Therefore, the presence of plants alkaloids did not affect 
recombinant mPrP solubility. Additionally, no detectable level of recombinant 
mPrP was found in the pellets.  
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6.2.2.5 Transgenic leaves lysed with buffers D and E 
To determine if ionic strength had any effect on protein aggregation and protein 
affinity for nickel ions, transgenic plants expressing the ER constructs were lysed 
with medium and low ionic strength buffers (Buffers D and E) at a tissue to buffer 
ratio of 1:2. These buffers also included 2-mercaptoethanol, a reducing agent 
expected to break up aggregates linked by disulphide bonds.  The clarified lysate 
was fractionated using His GraviTrap Talon column (GE Healthcare) charged with 
cobalt (Co2+) ions. Various fractions were analysed by western blot as shown in 
Figure 6.6. The results indicate that medium ionic strength buffer (Buffer D) did 
not improve the binding efficiency of the recombinant protein while the low ionic 
strength buffer (Buffer E) improved binding affinity, but the bound recombinant 
Figure 6.5: Ammonium sulphate fractionation of transgenic tobacco leaves 
expressing recombinant mPrP in the ER.  Tobacco leaves were lysed with Buffer 
C without 8M urea, precipitated by ammonium sulphate in 10% fractions and the 
precipitate resuspended in Buffer C.  Fractions were analysed by Western Blot, 
probed using HRP conjugated 6X-His-tag antibody (1:2,500 dilution). Lane 1: 20% 
precipitate. Lane 2: 30% precipitate. Lane 3: 40% precipitate. Lane 4: 50% 
precipitate. Lane 5: 60% precipitate. Lanes 7-8: Plant pellets solubilized in Laemmlli 
buffer. Lane 9: Control – recombinant mPrP from E. coli. 
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mPrP was eluted in the wash step. Neither buffer D nor buffer E improved 
recombinant mPrP solubility. 
 
 
6.2.2.6 Transgenic leaves lysed with buffer F 
To investigate if the detergent triton X 100 had an effect on recombinant mPrP 
aggregation, transgenic tobacco leaves expressing the recombinant mPrP 
construct were lysed with buffer F at a 1:20 ratio (tissue: buffer). The clarified 
lysate was fractionated using His GraviTrap Talon column (GE Healthcare) 
charged with cobalt (Co2+) ions. The resulting fractions were analysed by western 
blot as shown in Figure 6.7. From the result, lane 8 the eluted fraction contained 
heterogeneous bands. The high intensity ~19 kDa band represents 
unglycosylated aminoterminally truncated mPrP. A C-terminal histidine-tag was 
Figure 6.6: Purification of His-tagged recombinant mPrP from transgenic 
tobacco leaves extract. Tobacco leaves expressing recombinant mPrP in the ER 
were lysed with Buffer D or E and IMAC fractionated. Fractions were collected during 
the purification process and analysed by Western Blot, probed using HRP conjugated 
6X-His-tag antibody (1:2,500 dilution). Lane 1: Protein standard. Lane 2: Buffer E 
Lysate. Lane 3: Buffer D lysate. Lane 4: Buffer E flow through. Lane 5: Buffer D flow 
through. Lane 6: Buffer E first wash. Lane 7: Buffer D first wash. Lane 8: Buffer E 
eluate. Lane 9: Buffer D eluate. Lane 10: Control – recombinant mPrP from E. coli. 
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used indicating that the truncation occurred in the N-terminal. The low intensity 
bands indicates ~24 kDa unglycosylated mPrP, ~31 kDa high mannose 
glycoform and the ~54 kDa unglycosylated dimer. Hence, changing the detergent 
and diluting the lysate improved the binding efficiency. However, only small 
quantities of the full length glycoforms were recovered. Therefore, more efficient 
lysis of transgenic plant is required to improve IMAC fractionation of the 
recombinant mPrP. 
 
 
 
 
 
 
Figure 6.7: Purification of His-tagged recombinant mPrP from transgenic 
tobacco leaves extract. Tobacco leaves expressing recombinant mPrP in the ER 
were lysed with Buffer F and IMAC fractionated. Fractions were collected during the 
purification process and analysed by western blot, probed using HRP conjugated 6X-
His-tag antibody (1:2,500 dilution). Lane 1: Protein standard. Lane 2: Lysate. Lane 3: 
Flow through. Lane 4 – 6: Washes. Lane 7: Eluate 1. Lane 8: Eluate 2. Lanes 9 & 10: 
Blank. 
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6.3 Discussion  
Recombinant proteins produced in plant leaves are usually purified by 
chromatography based methods with purification strategies customised for each 
protein based on characteristics such as solubility, affinity to specific ligands, 
isoelectric point, size and charge (Chen, 2008; Wilken and Nikolov, 2012). 
Recombinant proteins are extracted by homogenisation in a buffer. The 
extraction process may be enhanced by evaluating buffer components, 
homogenisation technique, size distribution of particles in the extract, subcellular 
compartment of the recombinant protein and plant tissue to buffer ratio to limit 
molecular interactions between plant cell components and the recombinant 
protein (Wilken and Nikolov, 2012). Common buffer additives includes ascorbic 
acid, polyvinyl polypyrrolidone (PVPP), β-2-mercaptoethanol (B-ME) and 
dithiothreitol (DTT) to reduce phenolic compound interactions, detergents to 
solubilise membrane proteins and chlorophyll expressed proteins and proteases, 
antioxidants and metal chelators to prevent protein degradation (Wilken and 
Nikolov, 2012). 
The leaf extract is clarified to separate the solid debris from the extract by dead-
end filtration or centrifugation. At this stage, the clarified extracts contain various 
levels of phenolic compounds, alkaloids, native proteins, polysaccharides, DNA 
and chlorophyll pigments that foul the chromatographic resin and bind the 
recombinant protein, reducing the purification efficiency and quality of the 
recombinant protein. Therefore, the extracts are further conditioned or pre-
treated, depending on the nature of the recombinant protein, by ammonium 
sulphate precipitation, acidification or aqueous two phase partitioning to remove 
contaminating plant elements and reduce native protein concentration   (Wilken 
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and Nikolov, 2012). Acidification (Balasubramaniam et al., 2003) and fractional 
ammonium sulphate precipitation (Desai et al., 2002)  removes native plant 
proteins including ribulose-1, 5-biphosphate carboxylase/oxygenase (rubisco) 
which accounts for about 50% of native plant proteins, cell debris, chlorophyll 
pigments and aggregates . Aqueous two-phase partitioning effectively removes 
plant alkaloids, phenolic compounds and reduce tobacco native proteins that foul 
the chromatographic resin (Chen, 2008; Platis et al., 2008). Finally, proteins are 
purified mainly by a variety of adsorption chromatography methods as they offer 
higher resolution than other purification methods (Chen, 2008; Wilken and 
Nikolov, 2012). Recombinant antibodies expressed in tobacco plants are usually 
purified at above 90% purity by protein A or G affinity chromatography usually 
followed by an anion/cation exchange polish step (Vezina et al., 2009; Bendandi 
et al., 2010; Lai et al., 2010). Recombinant fusion proteins are purified based on 
their affinity tags. For example, β-glucronidase fused to calmodulin was purified 
from tobacco leaves based on the calcium dependent calmodulin affinity for 
phenothiazine affinity column (Desai et al., 2002). Also, interferon gamma fused 
to His-tagged -glucuronidase was purified from tobacco chloroplast in a two-
step process of anion exchange chromatography followed by IMAC purification, 
with 75% protein yield (Leelavathi and Reddy, 2003). 
The structural and chemical diversity of proteins requires elaborate downstream 
processes designed for isolating each protein, hence, affinity tags enables 
generic purification of a variety of recombinant proteins (Waugh, 2005). Hochuli 
et al. (1988) demonstrated that addition of polyhistidine-tags (H6) to the 
polypeptide sequence of recombinant proteins facilitated its purification in a 
single step process using IMAC technology. The basis of IMAC technology is the 
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interaction between immobilised transition metal ions (Cu2+, Ni2+, Co2+, Zn2+) and 
imidazole side chains of histidine residues (Bornhorst and Falke, 2000; Arnau et 
al., 2006). In addition to facilitating protein purification, polyhistidine-tag may 
affect the biochemical process of the protein positively by preventing proteolysis, 
protecting antigenicity, increasing solubility, improving yields and facilitating 
protein refolding. On the contrary, polyhistidine-tag may have a negative effect 
on the protein by hindering enzyme activity, changing the biological activity or 
structure of the protein and reducing protein yield. In cases when the 
polyhistidine-tag has a negative impact the tag may be cleaved by endoproteases 
or exopeptidases (Arnau et al., 2006; Waugh, 2005). 
IMAC purification of His-tagged proteins is cheap, easily scalable and optimised, 
protein can be purified denatured or in its native conformation. Also, IMAC resin 
is inexpensive, amenable to most buffers, has a high protein capacity (2-10mg/ml 
resin), and easily regenerated. Furthermore, purification is rapid often in a single 
step, up to 90% purity and 95% recovery of recombinant proteins have been 
achieved using IMAC technology (Bornhorst and Falke, 2000; Ueda et al., 2003). 
However, proteins with low expression levels may not be adequately purified 
using IMAC technology. Such proteins may require another affinity tag or 
purification step (Bornhorst and Falke, 2000). Also, IMAC purification of 
membrane proteins have been problematic, His-tagged membrane proteins do 
not bind to IMAC resin when solubilised in certain detergents. This is because 
the detergent micelle around the protein-detergent complex may block access to 
the histidine-tag completely or partially. Usually detergents are screened to 
determine the most suitable for both protein solubilisation and purification. 
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Alternatively, longer histidine-tags (H10) are used to improve the interaction 
between the recombinant protein and IMAC resin (Block et al., 2009). 
Purification of cellular prion protein (PrPC) has been demonstrated in various 
expression systems. PrPC was purified 13,000-fold with 17% recovery from 
Syrian hamster brain homogenates (Pan et al., 1992). Microsomal fractions of 
homogenised Syrian hamster brain were solubilised with Triton X-114 digested 
with phosphatidylinositol-specific phospholipase C (PIPLC) to cleave the GPI 
anchor and phase partitioned at 37oC. The aqueous phase was precipitated with 
PEG and solubilised in 8% ZW 3-12, followed by IMAC fractionation and cation 
exchange chromatography. Finally, the enriched fractions were purified by   SDS-
PAGE electrophoresis. Also, recombinant mouse PrPC expressed as insoluble 
inclusion bodies in E. coli BL21 (DE3) cells was purified by two cation exchange 
chromatography steps (Hornemann et al., 1997). Recombinant mPrP inclusion 
bodies were solubilised in 8M urea, the denatured protein was purified by cation 
exchange chromatography and disulphide bond oxidised by atmospheric oxygen 
in the presence of 1µM Cu2+ catalyst. Subsequently, urea was removed by 
dialysis and refolded mPrP was purified to homogeneity by cation exchange 
chromatography. Furthermore, truncated recombinant mPrP (residues 23-230) 
expressed in Chinese hamster ovary CHOL761h cells was purified in its native 
form by low pressure cation exchange chromatography and IMAC steps or 
reverse chromatographic steps and the recombinant protein was resolved 98% 
pure by SDS-PAGE and silver staining analysis (Brimacombe et al., 1999).  
Detergents, because of their unique physical and chemical properties, interact 
with other molecules in a complex manner. Detergents solubilise hydrophobic 
and amphipathic molecules into mixed micelles or micellar aggregates at 
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concentrations above its critical micelle concentration (CMC) (Garavito and 
Ferguson-Miller, 2001). Detergents also associate with the hydrophobic surface 
of membrane proteins to create protein detergent complex (PDC) that are soluble 
in water.  Researchers have observed that detergent micelles are quite fluid and 
can change micellar shape especially in the presence of proteins, lipids and other 
detergents. Therefore, solubilisation of a membrane protein depends on the 
choice of detergent, buffer composition, ionic conditions, detergent concentration, 
the presence of lipids and other proteins and experimental conditions (Fink, 1998; 
Garavito and Ferguson-Miller, 2001). Furthermore, membrane protein solubility 
depends on detergent-protein, detergent-detergent and detergent-lipid 
interactions. For instance, the flexibility and packing efficiency of protein-bound 
detergent monomers affects the stability and behaviour of the detergent layer. In 
turn, this detergent characteristic affects the solubility, stability and 
characterisation of membrane proteins and may result in inefficient protein 
solubility or protein aggregation (Garavito and Ferguson-Miller, 2001).  
In prior attempts at prion purification, several detergents were tested for their 
ability to solubilise precipitated microsomal fractions of Syrian hamster brain 
homogenates. Pan et al. (1992) solubilised PEG precipitated pellets in either 
SDS, sarkosyl, triton x-100, triton x-114, β-octyl glucopyranoside or zwittergent 
3-12. The pellets were almost completely solubilised by SDS and sarkosyl, β-
octyl glucopyranoside and zwittergent 3-12 solubilised approximately 90% of the 
pellets while triton X-100 and triton x-114 solubilised 50% - 60% of the pellets. 
However, SDS and sarkosyl were unsuitable for IMAC fractionation but PrPC 
binds to the Cu2+−IMAC resin in the presence of other detergents. In another 
study Turk et al. (1988), examined the effect of detergents and chaotropes on the 
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adsorption of PrPC to immobilised monoclonal antibody. PrPC did not effectively 
bind the immobilised antibody in the presence of 1% Nonidet P-40, 0.5% CHAPS, 
or 0.5% sodium cholate while 0.5% zwittergent  3-14, 0.5% zwittergent 3-16, and 
0.5% sodium deoxycholate increased the affinity of PrPC  for the immobilised 
antibody. The most effective detergent for affinity purification of PrPC were the 
zwittergent series and their effectiveness was improved in the presence of 0.3M 
guanidum thiocyanate.  
In this study, attempts to purify the His-tagged recombinant prion proteins from 
mature leaves of transgenic tobacco plants expressing either the cytosolic or 
endoplasmic reticulum constructs were based on IMAC chromatography utilising 
a C-terminal histidine-tag added to the expression construct. Aglycosylated 
recombinant prion protein were successfully purified from the cytosol in a one 
step process using buffer A. However, recombinant mPrP was prone to 
aggregation when extracted with the non-ionic detergent triton X-100. 
Presumably, aggregation affected the accessibility of the histidine-tag, to the 
metal ions used as affinity ligands resulting in loss of the protein in the flow 
through and wash eluates. Altering the buffer composition by varying salt 
concentration, buffer compounds and use of denaturing agents had no effect on 
disaggregating recombinant mPrP soluble aggregates or improving the 
adsorption of the recombinant mPrP on IMAC columns. Furthermore, ammonium 
sulphate precipitation to remove plant phenolic compounds from the recombinant 
protein had no effect on the prion aggregates or their affinity for metal ions. 
However, diluting the lysate 20-fold in buffer F which contained the zwitterionic 
detergent CHAPS resulted in eluted protein although most of the eluted protein 
appeared to be truncated by limited proteolysis showing a molecular weight of ~ 
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19 kDa on SDS-PAGE (Figure 6.7). Essentially, the zwittergent detergents were 
compatible with immunoaffinity chromatography and IMAC chromatography in 
PrPC purification from Syrian hamster brain homogenates (Pan et al., 1992; Turk 
et al., 1988), thus may solubilise recombinant PrPC expressed in transgenic 
tobacco plants 
Inexplicably, buffer B lysates were negative in all western blot experiments, thus 
buffer eluates were buffer exchanged to deionised water before the blotting 
procedure. Subsequent changes in the buffer composition improved the quality 
of the blots, perhaps due to increased concentration of the lysate. Also, addition 
of 8M urea did not improve the solubility of the recombinant mPrP aggregates in 
the presence of triton X-100, indicating that possibly the hydrophobic core of the 
protein detergent complex was inaccessible to urea. This phenomenon was 
observed by (Ruiz and Sanchez, 1994) who demonstrated using fluorescent 
probes that urea has no effect on the micellar core of triton X-100. Furthermore, 
the aggregated mPrP had no affinity for the immobilised metal ions, indicating 
that possibly the hexahistidine-tag was inaccessible within the aggregates and/or 
triton x-100 micelles prevented interaction between the hexahistidine-tag and the 
immobilised metal ions. In one study, triton x-100 micelles prevented association 
between lactate dehydrogenase enzyme and immobilised Cibarcron Blue F3GA 
dye in a dye-ligand affinity chromatography experiment. Although, addition of 
anionic detergents (SDS or deoxycholate) reversed this effect, the anionic 
detergents had no denaturing effect on the protein as it was sequestered by triton 
x-100 (Robinson et al., 1980). However, IMAC purification of membrane-
associated prion protein from microsomal fraction of Syrian hamster brain 
homogenates in the presence of triton X-100 has been demonstrated by Pan et 
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al. (1992). Therefore, the hexahistidine-tag may have a negative effect on 
solubility of the recombinant mPrP in non-ionic detergents. Alternatively, the 
insolubility of  protein in the presence of Triton X-100 represents evidence that 
recombinant mPrP produced in the cytosol and sequestered to the endoplasmic 
reticulum of transgenic tobacco plants have  PrPSc-like properties. 
A previous attempt at glycosylated prion purification, isolated the microsomal 
fraction by subcellular fractionation before detergent solubilisation of membrane-
associated protein (Pan et al., 1992; Turk et al., 1988). However, this study 
attempted to isolate both aglycosylated and glycosylated prion protein from 
clarified lysate of transgenic tobacco plants, this may have affected the solubility 
of the recombinant protein in triton x-100, as Kuczius and Kelsch (2013) observed 
that in the presence of copper and zinc ions unglycosylated prion protein was 
insoluble in triton x-100. However, it is unlikely that the concentration of metal 
ions used in this study are similar to levels in tobacco plant. Further optimisation 
of the purification of recombinant mPrP from transgenic tobacco plants will 
require high-throughput detergent screening for recombinant mPrP solubility and 
IMAC purification. Alternatively, expressing the recombinant protein without 
hexahistindine tag may improve the protein solubility and thus simplify the 
purification process as IMAC purification protocol for PrPC without hexahistindine 
tag has already been established (Pan et al., 1992). 
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PrPC encoded by the PRNP gene is a glycoprotein that is predominantly 
expressed in the neurons of mammals although its function is unknown. Post-
translational misfolding of PrPC due to the presence of genetic mutations, 
infection or spontaneous conformational change results in a deleterious isoform 
PrPSc (Prusiner, 1998). Prion disease is a fatal neurodegenerative disorder 
caused by the accumulation of PrPSc in the neurons (Prusiner, 1998). Currently, 
no reliable diagnostic procedure or therapy exists for the disease due to 
difficulties understanding the molecular mechanisms underlying the conversion 
from PrPC to PrPSc (Puoti et al., 2012).  
This study was designed to produce recombinant mPrP in transgenic tobacco 
plants for studies on the prion phenomenon. There are several advantages 
associated with producing recombinant proteins in transgenic plants over 
bacterial systems, especially mammalian-like post-translational modification 
(Twyman et al., 2005). In addition, the presence of recombinant mPrP in 
transgenic tobacco plants resulted in phenotypic alternations, which may help 
determine the function of the prion protein.  
Synthetic mPrP transgene constructs were designed to target recombinant mPrP 
to the apoplast, cytosol and endoplasmic reticulum of transgenic tobacco plants. 
The cytosolic construct and ER-targeted construct were successfully integrated 
into several transgenic tobacco lines. The transgenic lines were characterised to 
determine the quality of the recombinant prion protein and its effect on plant 
nutrients. 
Characterisation of transgenic plants targeting recombinant mPrP in the cytosol 
revealed that the recombinant proteins were likely to be misfolded and present in 
two isoforms, a ~24 kDa aglycosylated isoform and a ~19 kDa partially truncated 
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isoform. ELISA analysis showed that transgenic line C7 had the highest 
expression level at 0.0024% TSP.  
Phenotypic analysis of transgenic lines showed that the average level of iron was 
significantly upregulated in transgenic plants expressing cytosolic-mPrP 
compared to control plants. Furthermore, the average level of manganese was 
higher in plants expressing cytosolic-mPrP compared to other transgenic lines 
analysed. However, this result was not significant given the spread of the data. 
Analysis of peroxidase activity showed that mPrP may modulate antioxidant 
activity in transgenic tobacco plants expressing cytosolic recombinant mPrP and 
kanamycin treatment of transgenic lines expressing cytosolic-mPrP inhibited root 
development.   
Recombinant mPrP directed to the endoplasmic reticulum of transgenic tobacco 
plants were likely to be misfolded and  present in three isoforms; an 
unglycosylated ~24 kDa protein; a ~19 kDa truncated isoform and a ~31 kDa 
presumably high mannose glycoform. The transgenic lines examined had low 
expression levels with the highest expression from transgenic line E4 at 0.0016% 
TSP. Phenotypic analysis showed that the average Cu2+ levels was higher in 
transgenic plants expressing recombinant mPrP in the cytosol compared to other 
analysed transgenic lines. Furthermore, peroxidase activity was inhibited in 
transgenic plants producing recombinant mPrP in the endoplasmic reticulum. 
However, kanamycin treatment had no visible phenotypic effects on transgenic 
plants transformed with the ER transgene construct. 
Purification of recombinant mPrP from transgenic lines expressing both the 
cytosolic and endoplasmic reticulum constructs was abortive. The purification 
process was compromised by the low expression rates of the recombinant mPrP 
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coupled with the oligomeric and misfolded conformation of the recombinant 
protein. Muller et al. (2005), showed that unless denatured, PrPSc does not bind 
Cu2+ charged IMAC columns. Since Cu2+ has the highest affinity for histidine-tags, 
this implies that Ni2+ and Co2+ charged columns will not bind the misfolded mPrP. 
Therefore, the purification results indicates a PrPSc-like nature of recombinant 
mPrP targeted to the cytosol and ER of transgenic tobacco plants.  
Future research on recombinant mPrP purification should focus on assays to 
isolate IMAC compatible detergents/denaturants that can solubilise recombinant 
mPrP. For instance, Schlager et al. (2012) demonstrated that SDS can be used 
to denature proteins prior to IMAC purification since excess detergent can be 
removed by cooling the lysate. Furthermore, production of recombinant mPrP in 
tobacco cell suspension cultures could simplify the downstream purification 
process. Plant cell suspension cultures have several advantages over transgenic 
plants. For instance, they have a shorter growth cycle, transgenes can be 
designed to secrete the recombinant protein into the growth media simplifying the 
purification process and plant suspensions cultures have low environmental and 
contamination risks (Plasson et al., 2009). Examples of biopharmaceuticals 
produced in tobacco Bright Yellow-2 (BY-2) suspension cells include human 
growth hormone and hepatitis B surface antigen (Santos et al., 2016). 
This study has shown for the first time that mutant recombinant mPrP is 
processed in transgenic tobacco plants in a similar manner to animals 
establishing tobacco plants as a suitable production system for recombinant 
mPrP. The PR1a signal peptide appeared to direct recombinant mPrP to the ER 
due to the presence of glycosylated recombinant mPrP isoforms in transgenic 
lines transformed with the ER construct. In addition, the presence of the 
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hexahistidine-tag and/or the ER retention sequence did not affect the protein’s 
characteristics. Further research should focus on developing plants that produce 
fully glycosylated recombinant mPrP. Several studies have shown that the C-
terminal GPI anchor is required for synthesis of fully glycosylated recombinant 
mPrP. To simplify downstream processing, mutating selected amino acids in the 
GPI anchor signal sequence results in a correctly folded and fully glycosylated 
recombinant prion protein that is secreted rather than anchored to the plasma 
membrane (Walmsley and Hooper, 2003).  
Consumption of BSE-infected beef has been associated with variant CJD in 
humans (Brown et al., 2001). Mishra et al. (2004), demonstrated that treatment 
of sporadic CJD PrPSc molecules with digestive enzymes resulted in N-terminally 
truncated PrPSc fragments similar to treatment with proteinase K. Additionally, 
PrPSc binds ferritin and the PrPSc-ferritin complex can be transported across 
epithelial cells into the bloodstream. This PrPSc-ferritin association is independent 
of PrP concentration and indicates a possible transmission route for PrPSc. 
Corroboratively, PRNP ablated mice exhibit an iron deficiency phenotype 
indicating a possible role for PrPC in iron transport (Singh et al., 2009). This study 
has shown that expression of cytosolic-mPrP in transgenic tobacco plants 
increases uptake of iron in transgenic tobacco leaves irrespective of the 
concentration of recombinant mPrP in the leaves. Therefore, this study agrees 
with the suggestion that PrP has a role in iron homeostasis. Further investigations 
into the molecular mechanisms involved in PrP-associated uptake of iron will help 
elucidate the role of PrP in iron homeostasis and its contribution to PrPSc-
associated neurotoxicity.  
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Studies of brain tissue from patients with prion disease have revealed increased 
concentrations of Mn2+ and Zn2+ ions with a reduced Cu2+ ion content. 
Furthermore, Brown et al. (2000) showed that only Mn2+ ions can replace Cu2+ 
ions in prion protein and that Mn2+ -associated PrPC becomes protease resistant 
in a time dependant manner. In this study, independent transgenic lines 
expressing cytosolic-mPrP had elevated levels of Fe2+ and Mn2+ while 
independent transgenic plants with recombinant mPrP retained in the 
endoplasmic reticulum had elevated levels of Cu2+.  Consequently, this study 
shows for the first time that irrespective of PrP conformation its affinity for metal 
ions may depend on its subcellular localisation.  
It has been suggested that PrPC may be involved in maintaining zinc homeostasis 
in neuronal cells (Watt et al., 2012). Conversely, others have demonstrated no 
relationship between PrPC and zinc homeostasis (Pass et al. (2015). Expressing 
recombinant mPrP in transgenic tobacco plants had no effect on zinc levels in 
transgenic tobacco leaves probably because of the subcellular localisation of the 
recombinant protein. Future research should focus on expressing anchored 
mPrP in plants to determine the effect that localising recombinant mPrP to plasma 
membranes has on the metal ion content and antioxidant activity of transgenic 
tobacco leaves. Also, studies that direct mPrP to other plant organelles could be 
useful in the elucidation of the function of recombinant mPrP. 
The prion protein has three different topologies. The fully translocated PrP that 
can be secreted and two transmembrane forms. The N-transmembrane form 
(NtmPrP) has the amino terminus in the ER and the carboxyl terminus accessible 
to proteases in the cytosol while the C-transmembrane form (CtmPrP) has its 
carboxyl terminus in the ER and the amino terminus accessible to proteases in 
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the cytosol (Hegde et al., 1998). This study agrees with research that has 
suggested that high concentrations of PrPC in the cytosol is responsible for the 
toxic effects associated with prion disease (Sections 5.2.2 and 5.3).  The toxic 
effect of cytosolic PrP on neuroblastoma cells and cerebellar granular neurons 
(Ma and Lindquist, 2002) can probably be explained by increased Mn2+ 
concentration in the cells due to overexpression of PrP in the cytosol.  To 
substantiate this theory, Mn2+-induced neurotoxicity has been documented in SK-
ER3 neuroblastoma cell lines (Di Lorenzo et al., 1996) and cerebellar granular 
neurons (Hernandez et al., 2011). Also, Mn2+-depleted cells are not susceptible 
to prion infection (Pass et al., 2015). Hegde et al. (1998) demonstrated that 
overexpression of the CtmPrP transmembrane topology, associated with A117V 
mutation of GSS, is neurotoxic to cells in the absence of PrPSc aggregates. 
Therefore, it is important to design studies that will determine if overexpression 
of CtmPrP and cytosolic PrP is associated with increased manganese uptake and 
NtmPrP increased copper uptake in neuronal cells.  
This study has also shown for the first time that the interaction of mPrP with 
kanamycin sulphate inhibits the protein’s ability to bind Cu2+ ions and Mn2+ ions 
and to modulate peroxidase activity. However, root morphogenesis was inhibited 
in kanamycin-treated transgenic plants transformed with the cytosolic transgene 
construct. Since the effects of this interaction could be subject to the subcellular 
location of the mPrP, future studies should focus on understanding the 
biophysical and biochemical implications of prion-kanamycin interaction and how 
it can be harnessed for diagnostic and therapeutic purposes. 
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9.1 Appendix A: Protease Digestion of recombinant mPrP 
 
 
 
 
 
 
500 mg of transgenic plant leaves was solubilised in 1 ml of Lysis Buffer (50 mM 
Tris-HCl (pH 8), 5mM β-mercaptoethanol, 1% CHAPS). The lysate was 
precipitated with methanol/chloroform and resuspended in 500 µl of reaction 
buffer (50 mM Tris-HCl (pH 7.5), 5mM CaCl2). 12.5 µg of proteinase K (Promega) 
was added to 250 µl aliquot of the solution and incubated at 37C overnight. The 
control aliquots were stored at -20C overnight. Subsequently, the reaction was 
analysed by western blot using the anti 6X his-tag antibody (Abcam). The results 
indicate that the ~19kDa aminoterminally truncated mPrP molecules from plants 
expressing either the cytosolic or ER constructs are not authentic PrPSc 
molecules. 
Appendix 9.1: Proteinase K digestion of transgenic plants expressing mPrP. 
Lanes 1 & 3: Proteinase k treated lysate from transgenic lines C9 & C12. Lanes 2 & 
4: Untreated lysate from transgenic lines C9 & C12. Lane 5: Molecular weight marker. 
Lanes 6 & 8: Proteinase K treated lysate from transgenic lines E4 & E10.  Lanes 7 & 
9 – Untreated lysate from transgenic lines E4 & E10. Lane 10: Control – recombinant 
mPrP from E. coli. 
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9.2 Appendix B: Deglycosylation of recombinant mPrP 
 
 
 
 
 
 
250 mg of plant leaves was solubilised in 500 µl of Lysis Buffer (10 mM sodium 
acetate, 100 mM β-mercaptoethanol; 0.5% SDS). 250 µl aliquot of the clarified 
lysate was treated with 20 µl (1 mU) of N-glycosidase A (Roche) and incubated 
at 37C for 3 hours. The control aliquot was incubated on ice for three hours. 
Subsequently, the reaction was analysed by western blot using the anti 6X his-
tag antibody (Abcam).  From the results, deglycosylation of recombinant mPrP 
sequestered in the endoplasmic reticulum was unsuccessful because of its 
aggregated state (Appendix 9.2; lanes 3, 4 and 5 above 50 kDa) of the 
recombinant protein.   
 
Appendix 9.2: Deglycosylation of transgenic plants transformed with the ER 
construct.  Lane 1: Molecular weight marker. Lanes 2 & 4: Untreated lysate from 
transgenic lines E4 & E10. Lanes 3 & 5: N-glycosidase A treated lysate from 
transgenic lines E4 & E10: Lane10: Control – recombinant mPrP from E. coli. 
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9.3 Appendix C: Western Blot analysis of recombinant mPrP 
 
 
A 
 
B 
 
 
 
 
 
 
 
 
 
Appendix 9.3: Western blot analysis of recombinant mPrP using PrP antibody 
C-20 (1:1000 dilution).  A: Transgenic lines transformed with the cytosolic 
transgene construct. Lane 1: Control - recombinant mPrP from E. coli. Lanes 3 – 
9: Clarified Lysate from independent transgenic lines, C1, C4, C7, C9, C12, C15 and 
C23 respectively. B: Transgenic lines transformed with ER transgene construct. 
Lanes 1 – 4: Clarified Lysate from independent transgenic lines E1, E2, E4 and E7 
respectively. Lane 5: Control – recombinant mPrP from E. coli. 
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100 mg of homogenised transgenic tobacco leaves were lysed in 200 µl of 2X 
laemmli sample buffer. The lysate was incubated for 10 minutes at 90C and 
clarified by centrifugation at 13, 000 rpm for 5 minutes. The clarified lysate was 
analysed by western blot using the PrP antibody C-20 (Santa Cruz biotechnology) 
as described in section 2.3.3.1. As shown in Appendix 9.3, analysis of 
recombinant mPrP from transgenic lines transformed with the cytosolic construct 
indicated a single band of ~38 kDa, indicating a dimer of the aminoterminally 
truncated mPrP while recombinant mPrP sequestered in the endoplasmic 
reticulum indicated two bands of ~38kDa and ~32kDa 
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9.4 Appendix D: Non-detergent lysis of transgenic tobacco leaves 
expressing cytosolic-mPrP 
 
 
 
 
 
 
100 mg of transgenic tobacco leaves were lysed in extraction buffer (200 mM Tris 
HCl (pH 7.5), 10 mM EDTA, 1 mM PMSF, 100 mM NaCl). The extract was 
clarified by centrifugation at 13,000 rpm for 15 minutes and precipitated with 
methanol/chloroform. The precipitate was resuspended in 50 µl of 2X laemmli 
buffer and incubated at 90C for 10 minutes. The resulting solution was analysed 
by western blot.  
The analytes in Appendix 9.3 constitutes 0.5 mg of homogenised leaves per µl of 
extraction buffer compared to Appendix 9.4 which constitutes 2 mg of 
homogenised leaves per µl of extraction buffer. The results indicate in spite of a 
4-fold difference in analytes concentration, the non-detergent lysis buffer had 
Appendix 9.4: Western blot analysis of cytosolic-mPrP in transgenic tobacco 
lines.  Lanes 1-4: recombinant mPrP from independent transgenic lines C4, C7, C9 
and C12 transformed with the cytosolic transgene construct. Lane 8: Control - 
recombinant mPrP from E. coli. 
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lower protein concentration. This implies that cytosolic recombinant mPrP may 
be membrane-associated or binds to other membrane associated proteins. 
9.5 Appendix E: Recombinant mPrP concentration 
The concentration of recombinant mPrP in transgenic plant lines as determined 
by ELISA analysis is shown in Appendix 9.5. 
 
 
Transgenic lines Average mPrP  
Concentration 
(ng/ 100 µl of 
lysate) 
Average Total 
soluble protein 
(ng/ 100 µl of  
lysate) 
mPrP as %(TSP) 
E1 1.495814 148384.5 0.001008066 
E2 0.606289 119138.5 0.000508894 
E4 2.360312 146125.9 0.00161526 
E7 0.776333 257027.5 0.000302043 
E10 1.951788 129715.4 0.00150467 
C4 0.912424 212776.3 0.000428819 
C7 2.44075 100588.9 0.002426462 
C9 1.218471 86874.95 0.001402557 
C12 1.726432 128731.7 0.001341109 
C15 2.031893 151215.8 0.001343704 
 
 
 
Appendix 9.5: Recombinant mPrP concentration 
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9.6 Appendix F: qRT-PCR Analysis 
Data in Appendix 9.6 shows an example of relative mRNA estimation for 
transgenic plants expressing cytosolic-mPrP using the Pfaffl (2001) method. 
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Appendix 9.6a: qRT-PCR Efficiency  
A) EF1 Standard; Slope = -3.128; Efficiency (EEF1) = 2.09 
B) PrP Standard; Slope = -3.212; Efficiency (EPrP) = 2.05 
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Plant 
lines 
CT PrP CT EF1 ∆CT PrP ∆CT EF1 (EPrP) ∆CTPrP (EEF1)∆CTEF1 Normalised 
Relative 
Quantity 
C4 24.10 26.56 0.00 0.00 1.00 1.00 1.00 
C12 23.22 25.94 0.88 0.62 1.87 1.58 
 
1.19 
C7 23.92 21.24 0.17 5.32 1.13  50.49 0.02 
C15 23.38 27.11 0.72 -0.55 1.67  0.67 2.51 
C9 23.89 25.60 0.20 
 
0.97 1.16 2.04 0.57 
 
 
Normalised relative quantity = (EPrP) ∆CT (PrP calibrator-sample) 
                                                                            (EEF1) ∆CT (EF1 calibrator-sample) 
 
 
Appendix 9.6b: Relative RNA quantification 
